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“Nobody will laugh long who deals much with opium: its pleasures even are of a 
grave and solemn complexion.” 
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Introduction 
This thesis focuses on three critical phases in the life journey of a person with an 
opioid use disorder (OUD) ; Initial, random intermittent opioid use, termed 
‘Recreational Sporadic Use’, transitioning to increased persistent opioid use, 
labelled ‘Intensified Sustained Use’, culminating in complete impulsivity and full 
opioid dependence, coined, ‘Loss of Control’. The crucial role of the neurobiology 
of dependence, explored in depth in this thesis, underpins these key phases in 
developing and sustaining an opioid dependence. Building on this framework the 
thesis unravels the effect of Adverse Childhood Experiences on the likelihood of 
experimenting with opioids and subsequently cultivating a dependence. It then 
recounts the effect of both dual diagnosis and concurrent benzodiazepine abuse on 
sustaining and intensifying one’s dependence until an individual eventually 
surrenders to the inevitable destructive effects of an opioid dependence and loses 
all voluntary control over their usage. The thesis then delves further into the lives 
of individuals with OUD by illuminating both positive and negative factors in 
their life journeys, which influence the remitting, relapsing nature of their illness. 
Invariably, given the neurobiological factors nourishing drug dependence the 
negative factors triumph, and relapse to drug use prevails. In unravelling the 
complexities of the neurobiology of dependence, this thesis, highlights that 
undoubtedly the best approach to help, support and where possible treat 
individuals with an OUD is under the umbrella term of harm reduction.  A special 
focus is placed on the harm reductive properties of methadone as a therapeutic 
agent in combatting OUD, with a particular emphasis on the need to educate all 
members of society on its therapeutic benefits. Undoubtedly, the most harrowing 
outcome for all in this often-thwarted journey is fatal overdose (OD), 
unfortunately the outcome for which far too many individuals succumb.  
Therefore, the most pivotal of harm reduction strategies to ebb the flow of death 
in OUD, ‘Take Home Naloxone Programmes’ (THNPs) are examined in the latter 
half of this thesis, with particular scrutiny given to Ireland’s THNP. As this thesis 
highlights, in Ireland, we have made much progress in our approach to addressing 
the opioid crisis but, as always, there is much room for improvement and 
advances.  
Aims 
The predominant aim of this thesis echoes a key strategic purpose of Ireland’s 
latest drug strategy, ‘Reducing harm, supporting recovery: a health-led response 
to drug and alcohol use in Ireland 2017- 2025’, which is to reduce the morbidity 
and mortality associated with OUD. Two studies are undertaken to achieve this 
purpose. Study 1 aims to give clients of the Mid-West of Ireland’s Programme for 
Methadone Maintenance Treatment (MMT) a voice, to document their lived 
experience of opioid dependence before, during and after their ‘three-phase 
journey’ through OUD. It aims to co-develop with clients a tailored care plan to 
enhance their chance of successfully engaging with the MMTP. Study 2 aims to 
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gain an overall appreciation of Ireland’s national THNP to optimise its 
functioning. A second objective of this study is to improve the likelihood of a 
patient attending hospital post administration of naloxone in the community, a 
step that is associated with overall better survival rates.   
Methods 
This thesis employs a mixed method research design. Study 1 is a qualitative study; 
Study 2 employs a quantitative method.  
Results 
Study 1 reveals an enriching insight into the personal experience of each 
individual client’s journey. Their journeys, though each unique, had common 
chronological sub-themes which are recounted in depth. Subsequent data analysis 
identifies common life experiences, which influence their journey both negatively 
and positively. Final data analysis identifies clients’ individual suggestions for 
improving their journey. The results of Study 2 reveal inadequacies in the current 
reporting mechanism currently in place on the use of naloxone in the community 
setting in Ireland. Descriptive analysis then looks at the characteristics pertaining 
to overdose patients themselves and subsequently the characteristics of the 
overdose scene are documented. Thereafter, using a logistical regression model, 
statistical results on the variables that influence a patient’s hospital attendance are 
presented.  
Conclusion   
The thesis concludes with recommendations for improvement in the management 
of OUD. It proposes how knowledge of ACEs should influence the MMTPs in 
Ireland and internationally, to adopt a more ‘trauma informed’ ethos. 
Subsequently, recommendations centre on dually diagnosed individuals, with a 
specific focus on addressing benzodiazepine misuse. Next, the theme of 
therapeutics is explored, listing specific proposals on how to both promote 
education and reduce stigma in relation to methadone, as a treatment option in 
OUD. Finally, the thesis focuses on recommendations with regard to THNPs. 
Initial suggestions focus on improving the Irish THNP and subsequently general 
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Chapter 1 Introduction  
1.1 Chapter Overview 
This chapter first defines ‘Opioid Use Disorder’ (OUD). It then outlines the 
natural history of OUD, with a subsequent focus on the role of neurobiology, 
which underpins the evolution of OUD. Thereafter, the importance of ‘adverse 
childhood experiences’ (ACEs) in predisposing an individual to develop an OUD 
is summarised. The two main theories supporting drug dependency are then 
discussed. The latter half of the chapter delineates the global magnitude of OUD 
with a particular focus on both European and Irish landscapes. The mainstay of 
European management, ‘Opioid Agonist Treatment’ (OAT) is then explored. The 
harm reduction services available in the Irish service are then listed. Finally, 
overdose (OD) in the context of OUD is reviewed.  
1.2 Defining Opioid Use Disorder 
Abuse and misuse of opioids, termed an opioid use disorder (OUD), is a major 
health concern worldwide. (1) The opioid class of drugs comprises of natural 
opioids (e.g., morphine, codeine), semi-synthetic opioids (e.g., heroin, 
oxycodone) and synthetic opioids (e.g., methadone, buprenorphine, and fentanyl). 
(2) OUD is defined by the Diagnostic and Statistical Manual of Mental Disorders, 
Fifth Edition (3) as a “problematic pattern of opioid use leading to clinically 
significant impairment or distress, as manifested by at least two of the following, 
(Table 1 below) occurring within a 12-month period.”  
 
Of note, in 1964 a World Health Organisation (WHO) Expert Committee 
suggested that the term ‘dependence’ should be used in lieu of ‘addiction’ and 
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‘habituation’ (4) when referencing drug reliance. For the purpose of this thesis, 
the term ‘dependence’ will have specific reference to both the physical and 
psychological elements of opioid dependence. In terms of an OUD, physical 
dependence refers to points 10 and 11 of the diagnostic criteria as listed below, 
while psychological or psychic dependence implies compromised or weakened 
ability to control opioid use. 
  
Table 1: Diagnostic Criteria for an Opioid Use Disorder  
 
Reference: Diagnostic and Statistical Manual of Mental Disorders, fifth edition (3) 
* If two or three items cluster together in the same 12 months, the disorder is mild; if four or five 
items cluster, the disorder is moderate; and if six or more items cluster, the disorder is severe. 





No Diagnostic Criteria 
1. Use of an opioid in increased amounts or longer than intended. 
2. Persistent wish or unsuccessful effort to cut down or control opioid 
use. 
3. Excessive time spent to obtain, use, or recover from opioid use. 
4. Strong desire or urge to use an opioid. 
5. Interference of opioid use with important obligations. 
6.  Continued opioid use despite resulting interpersonal problems, social 
problems (for example, interference with work), or both. 
7. Elimination or reduction of important activities because of opioid 
use. 
8. Use of an opioid in physically hazardous situations (for example, 
while driving). 
9. Continued opioid use despite resulting physical problems, 
psychological problems, or both. 
10. Need for increased doses of an opioid for effects, diminished effect 
per dose, or both† 
11. Withdrawal when dose of an opioid is decreased, use of drug to 
relieve  withdrawal, or  both† 
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1.3 Natural History of OUD  
Evolution to drug dependence is composed of three successive and independent 
phases: successive, because admission to one phase is an essential stipulation to 
progress to the ensuing one; yet, independent, because entering one phase does 
not guarantee advancement to the next one. (5) 
Phase 1 encompasses occasional, infrequent drug use, coined by Piazza as 
“Recreational Sporadic (ReS) drug use”. Drug use is random and accounts for 
only a small percentage of the individual’s day- to -day, even week -to -week 
activities. This behaviour can be judged as routine and “normal” and is 
commonplace in a certain percentage of the population. (5) 
Phase 2, “Intensified Sustained Escalated (ISuE) drug use”, again coined by 
Piazza, commences with an escalation in occurrence, quantity, and incentive to 
acquire drugs. The ISuE phase is the first “moderate pathological state,” one in 
which the quantity of drug use is excessive but the individual’s conduct is still 
ordered. Everyday responsibilities are achieved and individuals still typically 
considered socially acceptable in society. (5) 
The third phase heralds the start of the most severe pathological condition. Now, 
the individual has “Loss of Control (LoC)” of drug consumption and develops 
complete dependency. Drug acquisition becomes the individual’s chief goal, 
occupying most of their time and energy. Subsequently, social degradation and 
deprivation is unavoidable, and relapse to drug taking—even after sustained 
periods of self-restraint—is inevitable. (5) 
It is important to highlight that during the evolution from “recreational” to 
“sustained” drug use, the first noticeable change in drug consumption is 
quantitative in nature. When transitioning from “sustained” use to “loss of 
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control” over use then the alteration is of a qualitative nature, the primary 
modification being not the quantity of the drug consumed but the individual’s now 
inability to restrict substance intake, a qualitative change.  
1.4 The Neurobiology of Drug Dependency 
The neurobiology of drug dependency underpinning the above ‘three phase 
process’ is expanded upon in the following section.  
1.4.1 Phase 1 
Phase 1 on the path to developing a substance use disorder (SUD) is due to an 
increase in dopamine release in the brain’s nucleus accumbens, particularly the 
nuclear shell. Dopamine is a brain neurotransmitter that modulate amongst others, 
cognition, drive, and pleasurable emotions. The primary over-excitation of this 
system by opioids, which incentivises our natural behaviours, yields the euphoric 
effects of drugs, ensuring they are extremely likeable and pleasant and initially 
drives the recreational use of drugs.  
1.4.2 Phase 2 
Incorporating both a psychological and biological component, four core theories 
underpin Phase 2 ‘the evolution from ReS to ISuE’. 
1.4.2.1 Theory 1 
Increased sensitivity to dopamine 
Firstly, the motivational influences of drugs intensify, or sensitize, in the 
evolution of escalated and sustained drug use. For nearly 30 years research has 
proven that individuals who are susceptible for acceleration to drug use have a 
‘spontaneously sensitized dopaminergic system’ (6) and an abnormally high 
response to their first experimentation with drugs. (7)  
20 
 
This sensitized reaction and the accompanying susceptibility to intensify ones 
drug use to a pattern of sustained use can be provoked by either repetitive stress 
or recurrent drug exposure. (8) When ‘stressed’, an upsurge in the transmission of 
dopamine is seen in the nucleus accumbens of vulnerable rats. (9) Advancing on 
this, later research showed that after intensified use, the motivational and 
fortifying aspects of drugs were amplified. (10) 
These and associated research findings propose an overall increase in the 
susceptibility of an individual’s motivational drive—driving the individual to 
increasingly desire drugs—as a strong component in the development of drug 
dependence. (11)  
1.4.2.2. Theory 2 
Impairment of the Pre-Frontal Cortex (PFC) 
A properly functioning PFC is necessary for healthy neuropsychological 
functioning as it exhibits control over emotion, reasoning and behaviour. This 
explains why PFC disturbance in drug dependence negatively affects a broad 
spectrum of behaviours.  
Imaging studies and pre-clinical investigations (12, 13) show a disordered 
functioning of the PFC gives rise to a syndrome that is typified by assigning 
undue importance to the drug and drug-related prompts, a diminished respect for 
non-drug related positive reinforcers and a decreased capacity to prevent 
maladaptive or destructive actions. (14)  
Because of these fundamental shortfalls, the search for and acquisition of drugs 
becomes the primary motivational force, sacrificing other undertakings (15) and 
climaxing in risky, often life-threatening actions in the quest for drugs. (16) 
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1.4.2.3 Theory 3 
Relationship between glucocorticoid hormones and the dopaminergic system  
One of the most critical controllers of dopaminergic activity in the accumbens is 
glucocorticoid tone. (17) Vulnerable rats produce a larger amount of 
glucocorticoids (18) and these hormones are an essential element in shaping their 
susceptibility to drug abuse (19). Glucocorticoid receptors (GRs) are expressed by 
neurons that distend back to the ventral tegmental area (VTA).  
Explicitly subduing the glucocorticoid receptors (GRs) in these neurons radically 
diminishes the overall activity of dopamine in the accumbens and induces a 
behaviour indistinguishable from abuse-resistant rats (8) In stark contrast, 
dispensing glucocorticoids repetitively escalates vulnerability to the self- 
administration of drugs. (20) As such, because of this GR over-stimulation, some 
individuals progressively desire additional quantities of a drug and have a greater 
susceptibility to cultivate ISuE. 
1.4.2.4 Theory 4  
‘Allostasis: a patho-physiological means that anchors sustained drug use’ 
Le Moal and Koob first suggested the foundation of an ‘allostatic state’ was a 
critical component in establishing drug dependency. (21) As such, following 
lengthy exposure to drugs, reward systems acclimatize to this everyday 
overexposure by altering the ‘homeostatic set point’ (allostasis) to adjust to this 
constant excessive stimulus. For this reason, the drug state gradually becomes the 
norm and the nondrug state is now sensed as a pathological, or at least, as highly 
undesirable and hostile. Drugs increasingly move from being intensely desired to 
also stalwartly required.  
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The chief first-hand evidence for this theory is the alteration of the ‘set point’ 
detected in rats that develop drug dependency. In such rats, the sensitivity of their 
incentive lessens and over time requires increased stimulation to attain the same 
level of reward. (22) With the evolution of a downregulated reward system, an 
individual’s progression to intensified, continued drug use is now complete.  
1.4.3 Phase 3 
The final step, phase 3, results from a compromised synaptic flexibility and with 
it the advancement to loss of control of drug use and full dependence.  
It is generally understood that synaptic malleability, controlled by ‘long-term 
potentiation’ (LTP) and by ‘long-term depression’ (LTD) within the synapses, 
denotes the brain’s ability to reinforce or dampen neuronal pathways in order to 
uphold adaptive behavioural responses to alterations in one’s environment. (23)  
If a significant incident results in a current behavioural sequence not providing 
adequate or appropriate adjustment to the environment or situation, the brain can 
dampen the synaptic power in the affected circuit and concurrently increase 
synaptic strength in a new circuit, thus facilitating a novel and more responsive 
behavioural sequence to respond to the needs of the individual. The equilibrium 
between potentiation (LTP) and depression (LTD) can vary from behaviour to 
behaviour preserving a malleable and adaptive behavioural response.   
In OUD, loss of this flexibility in regions such as the nucleus accumbens and the 
pre-frontal cortex, have devastating consequences. Behaviour remains crystallized 
around one behavioural goal, the acquisition and intake of opioids and cannot 
change to another. Pronounced doggedness to attain the ‘crystallized goal’ of 
opioid intake, no matter the losses or penalties is evident. Externally, this 
manifests as a substantial ‘loss of control’ over drug intake.  However, this is not 
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a state of obsessive pathological impetus for the drug but instead a ‘prison’ from 
which the behaviour preserved around one exclusive goal, drug consumption, is 
not very likely to evade. 
Pier Vincenzo Piazza and colleagues describe an excellent metaphor to explain 
this phenomenon. (5) It is to envisage that the brain is a chamber full of water and 
behavioural goals are containers of varying shapes. Under normal circumstances, 
one can simply remove a given container and immerse a different one, and alter 
behaviour. However, if the water freezes, i.e., crystallizes (loss of synaptic 
plasticity), it will trap the original contained behaviour (taking drugs), and one 
will be imprisoned in this behavioural goal. With some aid, much exertion, and 
grating (agonizing first stage of any detoxification treatment), you might succeed 
in extracting the original cylinder from the crystallized water. However, it will be 
unfeasible to plug the enduring cavity with any other behavioural container. One’s 
behaviour is now crystallized, you may adapt to living with the crater for a period 
(abstinence) but eventually the temptation will be too strong, given the occasion, 
(stress, exposure to drug paraphernalia) to re-fill it with the only container that 
fits: drug taking (rapid relapse to drug dependence even after lengthy abstinence). 
Of course, the water could melt and the individual could re-claim control or 
plasticity over its behaviours. However, this seems to occur in a very small subset 
of individuals; rather, drug dependence becomes a ‘frozen’ long-term relapsing 
disease in 90 % of instances. (5) 
In the case of drug dependence, research indicates that the areas governing drug 
use advance from the VTA to the accumbens and lastly to the cortex. Thus, on 
initial exposure, the VTA is modified but the accumbens appears fully unaffected. 
Subsequently, alterations in the accumbens appear but before the emergence of 
full drug dependence-like behaviours. The final area of modification is the 
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synaptic plasticity of the prefrontal cortex. (24) This data strongly supports the 
idea that the process of drug dependence is facilitated by independent but 
consecutive phases. 
1.5 Predisposition to OUD  
Of importance to note, though research indicates that recreational drug use can be 
considered customary behaviour in a certain cohort of the population, certain 
individuals are more predisposed than others are to drug seeking and taking 
behaviours, namely those who have experienced adverse childhood experiences 
(ACEs). ACEs are defined as, “stressful experiences occurring during childhood 
that directly hurt a child (e.g. maltreatment) or affect them through the 
environment in which they live (e.g. growing up in a house with domestic 
violence)”. (25) 
Felitti, Anda and colleagues in their groundbreaking study, “Relationship of 
childhood abuse and household dysfunction to many of the leading causes of 
death in adults: The Adverse Childhood Experiences (ACE) Study” first described 
ACEs in 1998. (26) Through a prospective study on 17,421 insured, well-educated 
adults, these researchers identified ten childhood experiences (tabled below), that 
have a clear association with the development of chronic illness in later life. (27) 
Their original study remains one of the most thorough research studies ever done 
on ACEs. In their study, ACE scores ranged from zero to 10 and were measured 
through a clear, straightforward ten-stem questionnaire, with each stem signifying 
one specific area of adversity. A positive answer accounts as one ACE. Five of the 
ten ACEs represent personal adversities with the remaining five relating to 





Table 2: Adverse Childhood Experiences 
Experiences Personal (abuse and 
neglect) 
Familial (household dysfunction) 
1. Emotional Abuse Loss of parent though divorce, 
death or abandonment 
2. Physical Abuse Mother treated violently 
3. Sexual Abuse Substance abuse in family 
4. Emotional Neglect  Mental illness in family 
5. Physical Neglect Incarcerated family member 
 
In Summary, the Felitti’s study found: 
 ACEs occur frequently. For instance, 28% of participants recounted 
physical abuse and 21% testified to experiencing sexual abuse. Many also 
described parental loss or parental mental health and/or having parents 
with a substance use disorder. 
 ACEs cluster. Nearly 40% of the participants recounted 2 or more ACEs 
and 12.5% suffered four or more. Because of this finding, subsequent 
studies focused on the aggregate consequences of ACEs rather than their 
individual influence.  
 ACEs have an exposure-response affiliation with long-term well-
being. Over time, research has found that an individual’s aggregate ACE 
tally has a robust, ranked correlation to various health, social, and 
behavioral issues during their life course, including the misuse of 
substances. In addition, many difficulties related to ACEs tend to cluster 
and co-occur.    
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It showed a definite causal relationship between the depth of exposure to personal 
abuse or family dysfunction during childhood and many of the risk factors for the 
leading causes of adult mortality, inclusive of illicit drug abuse.  Emotional 
control is the capability of a person to regulate their expressive state to adapt and 
deal with the stresses of their environment. Bowlby’s attachment theory is often 
referenced as a necessary step in acquiring the ability to successfully regulate 
one’s emotion. (28) If a child’s development is impaired, their aptitude to obtain 
competencies such as affect regulation may be compromised. This impairment 
often leads to dependence on avoidance coping mechanisms such as substance 
abuse, which in turn thwarts their development of self-regulation capabilities in a 
cyclical manner. (29)  
ACEs can set individuals on a path of self -destructive behaviours; intensifying 
their probability of embracing health-harming activities such as misuse and abuse 
of opioids. (25) A mounting body of research validates the persuasive long-term 
influence of ACEs on substance use disorders in adulthood.  (30, 31) 
Multiple childhood adversities may also be an indicator of more protracted and 
chronic exposure to stressors that are liable to result in a more lasting and intense 
negative effect than once off, solitary encounters. (32) Evidence shows that 
anxiety or traumatization from ACEs may result in enduring neurobiological 
modifications in the brain circuitry, escalating one’s vulnerability to stress-related 
health disorders and mental health illnesses, including drug dependence. (33) 
ACEs’ robust relationship with both physical and mental health illnesses is often 
explained by a complex interplay between genetic factors, epigenetic processes, 
dysregulation of stress related hormonal mechanisms (e.g. dysfunction in the 
production of cortisol in the hypothalamus-pituitary-adrenal axis), and immune 
factors. (34, 35) Self-medication or stress-reduction theories associated with 
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substance abuse also propose that ACEs lead to early commencement of 
substance misuse as a survival strategy, which can further promote the recurring 
interplay of hazardous activities, increased stress, and additional substance abuse. 
(32) Enduring this chronic, relentless stress in childhood can lock individuals into 
a greater state of constant vigilance, permanently primed to deal with further 
trauma. The negative psychological impact of ACEs can result in individuals 
suffering low self-esteem and promote a vulnerability for activities proposing 
short-term reprieve and sacrificing health and well-being in the long-term. This 
toxic combination results in affected individuals being inclined to engage in risky 
behaviours such as substance misuse. (36) Research also confirms that the 
correlation between ACEs and the ensuing establishment of a substance use 
disorder may be partially facilitated by post-traumatic stress disorders, mood, and 
anxiety disorders from ACEs. (37)  
Children of those affected by ACEs are at a heightened risk of exposing their own 
children to ACEs. (38) This perpetuation of ACEs is commonly known as the 
‘cycle of violence’. (39)  
This continuous cycle can lock generation into OUD. It follows that stopping 
ACEs in one generation or minimising their impact on children can help not only 
those individuals but also their offspring. Such a cycle of childhood adversity can 
lock successive generations of families into opioid dependence. Findings from 
this study were replicated in a recent systematic review and meta-analysis 
conducted in Wales (40) confirming the intergenerational effects of ACEs which 
can subject families to repetitive phases of misfortune, deprivation, and chronic 
illness.   
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Accordingly, inhibiting ACEs in a single generation or lessening their influence 
on children can help not only those individuals but also future generations. Public 
Health play a central role in breaking the cycle of violence but they require help 
and support from relevant community health care services such as Drug and 
Alcohol Services. (25) 
Even though ACEs may not be wholly preventable, interventions aimed at their 
early detection and suitable interventions for their subsequent removal is likely to 
play an important role in preventing the scourge of substance use disorder. Taking 
all the above into account, a convincing case exists for increasing international 
attention on averting ACEs, progressing programmes to augment resilience, and 
implementing procedures and practices that support both.  
1.6 Theories on drug dependency 
Stemming from the above research findings are two independent groups of 
theories on drug dependency, drug centred theories and individual centred 
theories.  
Drug focused theories are the ones most often cited in experimental research. This 
category of theories encompasses all viewpoints on drug dependence for which 
repetitive consumption of drugs is the chief foundation for drug dependence. 
These theories state that the psychopharmacological modifications that ensue due 
to chronic drug use result in dependency. The focus is on explicit drug-induced 
alterations, inclusive of tolerance (41), sensitization (42, 43), withdrawal and 
allostasis (44) or drug-provoked  transformations in cognitive function such as 
impulsivity (45), decision making (46), and conditioning. (43) These theories 
were strengthened by long-established research on the very substantial 
neurobiological alterations at molecular, cellular (47), synaptic (48), and network 
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levels (49, 50) that result from long-term drug consumption. Research confirming 
that the longer the ‘within- or between-day exposure to a drug’, the greater the 
probability of intensified drug intake (51) and the subsequent emergence of 
symptoms of ‘loss of control’ (52) also support this collective opinion.  
Individual focused theories agree that drugs are necessary for the development of 
drug dependence but are not in themselves wholly adequate in its cultivation. 
According to this theoretical agenda, a few susceptible individuals, with a 
vulnerable biological phenotype, succumb to a pathological response to the drug, 
and as a result, drug dependency ensues. Abundant research confirms that this 
phenotypic vulnerability results from a multifaceted interaction between genetic 
factors (53) environmental factors (54) developmental factors (55) and a specific 
inter-play between gene + environment interactions (56).  
The reason why the differences in both theories are important to note is not 
merely academic, they significantly influence both the medical treatment and the 
societal attitudes to drug dependence. The two families of theories generate 
opposing scientific, medical, and social understandings of drug dependence and 
advise opposing strategies to deal with this health issue.  
Drug-centred theories recommend resourcing strategies, which prevent exposure 
to drugs, by either preventative or repressive methods, such as criminalising drug 
use and/or punitive repercussions for its use. From a research perspective, a chief 
focus should be to isolate and reverse the brain alterations prompted by drug use. 
Individual-centred theories, classify drug dependence as a true psychiatric illness. 
Most psychiatric illnesses result from stimuli which though largely benign for the 
general population are extremely pathological for a cohort of susceptible 
individuals. Putting this in tangible parameters, from a psychiatric perspective, 
30 
 
anxiety disorders such as fear of spiders, arachnophobia, fear of germs, 
mysophobia, and fear of rats, musophobia which although are commonly 
experienced as disagreeable to many individuals do not prompt pathological 
responses in most people. Likewise, as defended by individual focused theories, 
drug consumption in the general population is not in itself, an adequate condition 
for drug dependence, as dependence occurs only in a subset of vulnerable 
individuals. Therefore, there is no reason to classify drug dependence differently 
from other psychiatric diseases.  
Most developed countries have unreservedly validated drug centred theories of 
drug dependence: Repressive and preventive measures account for the majority of 
public expenditure in relation to drug dependence, and most publicly subsidised 
drug dependence research examines the consequences of chronic drug 
consumption on brain physiology. Lastly, in most countries, an ‘addict’ is 
classified not as a person living with a mental illness but as an individual who 
became ‘addicted’ to a substance due to deficiency of willpower—as someone 
with an inherent flaw. Disappointingly, the destiny we retain for ‘addicts’ differs 
significantly from that of individuals with well-accepted psychiatric diagnoses, 
such as depression. In the latter instances, even persons undertaking major 
felonies are treated in tertiary psychiatric services and not imprisoned, as most 
often occurs to ‘addicts’. 
The individual centred theories do not refute the drug centred theories but believe 
they are a component of a more complex, individual disease process. In summary, 
the transition from the first to the second step of exaggerated, constant, intensified 
drug use occurs in a cohort of susceptible individuals who ha12ve an over-
sensitive response to dopamine and an impairment in the functioning of their 
prefrontal cortex. Persistent and protracted drug use fosters an ‘allostatic’ state 
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that ensures drugs are not only intensely desired but also fundamentally required. 
The evolution to the third and last step, ‘loss of control’ and full drug dependence, 
is due to a second susceptible phenotype, characterized by a long-term demise in 
synaptic flexibility in the brain’s reward circuitry in the brain inducing a form of 
‘behavioural crystallization’ resulting in drugs now not only being craved and 
needed but also pathologically bemoaned when absent. This is the working theory 
of this thesis and as such, the best treatment options tailored to treat opioid 
dependence are those based on the philosophy of harm reduction.  
1.7 The global magnitude of OUD 
The worldwide encumbrance of ailments from illnesses due to OUD approaches 
close to 11 million lost life-years from health issues, morbidities, and early 
mortality. (57) Approximately 16 million people around the world suffer with a 
current or previous OUD, of which nearly 3 million reside in the United States. 
(58) The ‘US Department of Health and Human Services’ declared the 
catastrophic misuse and abuse of opioids “a public health emergency” in October 
2017. (59) From a European perspective, statistics reveal that there are roughly 
1.3 million hazardous users of opioids in the EU where opioids are implicated in 
84% of fatal ODs. (60) In the EU, heroin is the most widespread opioid in the 
drug market. 2013 figures indicate it has an approximate minimum trade worth of 
EUR 6.8 billion (likely ranging from EUR 6.0 billion to EUR 7.8 billion). (60) 
Additional opioids obtainable on illegal European markets are inclusive but not 
limited to, opium and the medicines morphine, methadone, buprenorphine, 
tramadol and different fentanyl by-products. Several opioid compounds are re-
routed from authentic medicinal suppliers, while others are illicitly synthesised.  
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1.7.1 Health and Social Outcomes relating to OUD 
Literature reporting the medical problems linked with opioid misuse is plentiful 
and all outcomes signal that opioid‐related harms are intensifying. (61) Numerous 
factors compound the acute and chronic health complications linked with OUD 
inclusive of the pharmacokinetics and pharmacology of the opioids, their route of 
consumption, individual susceptibilities and the social environment in which 
drugs are consumed.  Acute physical harms include immunosuppression (62), 
endocrinopathies (63), opioid induced bowel dysfunction (64) and hypertension. 
(65) Psychological harms take account of sleep disturbance (66), anxiety (67), 
abusive and aberrant behaviour. (68) Evolution to intravenous drug use increases 
health risks such as cellulitis, phlebitis, abscesses (69) wound botulism and 
necrotizing fasciitis (70) and exposure to infectious diseases such as the human 
immunodeficiency virus, hepatitis C virus (71) syphilis and tuberculosis (72) are 
reported to be more prevalent in individuals with an OUD than in the general 
population.  
The typical life course of those with an opioid-use disorder comprises phases of 
deterioration and subsequent periods of remission, but the core susceptibility to 
opioid misuse never abates. (73) Once an OUD is diagnosed, the damaging effects 
on quality of life and well-being are considerable. The individual, familial and 
societal repercussions are also substantial. Illnesses resulting from insobriety or 
unlawful pursuits, such as skull trauma or gunfire injuries are also more frequent. 
(74). The toll associated with a reduced quality of life from OUD spreads beyond 
the personal, affecting the physical and mental well-being of the individual’s 
household, too. (75) From a societal perspective, escalating state expenditures 
related to healthcare, work force, and the law have a huge negative impact. (76) 
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Individuals with an OUD use considerably more healthcare resources, inclusive of 
the emergency services, community outpatient facilities, out-of-hours services and 
inpatient hospital departments. (77)  
There are a continuum of strategies available to positively impact on the 
encumbrance on OUD from diagnosis, treatment and rehabilitation to prevention 
(such as preventing ACEs or indeed creating supportive social environments for 
health) but the focus of this thesis will be on harm reduction strategies as advised 
by the Council of the Ministers of the EU.  
1.8 OUD in Europe 
In 2003, to tackle both the morbidity and mortality associated with OUD, the 
Council of the Ministers of the EU endorsed the need to prevent and lessen health-
related ills resulting from drug misuse. Member States were counselled to 
implement a number of relevant harm reduction policies. In 2007, the 
Commission of the European Communities ratified that drug-related harm 
reduction should be a public health objective in all countries. Therefore, in 
general, there is an understanding within Europe on the importance of decreasing 
harms, specifically the proliferation of infectious diseases and of course, drug 
related morbidities and death. The EMCDDA’s 2025 strategy (78), is dedicated to 
contributing to a healthier Europe by appropriately responding to the adverse 
health and social penalties associated with SUD.  It promises to keep abreast of 
harm-reduction approaches and to assist its stakeholders in identifying and 
implementing evidence-based practices.  
Currently, medical treatment with opioid agonist treatment (OAT), supported by 
psychosocial expertise, is the chief intervention for individuals with an OUD, and 
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ensuring appropriate, timely admission to optimum treatment facilities is a 
fundamental aim of the European drug strategy.   
1.8.1 Opioid Agonist Treatment (OAT) 
OAT has certain characteristics, which optimises its effectiveness including an 
oral rote of administration and a prolonged duration of action. An oral route of 
administration is more satisfactory to individuals improving Individual 
compliance. It removes the danger of contracting blood-borne diseases linked 
with intravenous drug use and the potential use of contaminated or shared drug 
paraphernalia. The symbolic association to an illegal lifestyle is broken and the 
need for individuals to congregate to share needles and syringes is eliminated. A 
24-hour interval between appropriate doses accommodates a once daily dosing 
regimen. It removes the occurrence of opioid withdrawal symptoms. Key 
physiological functions unsettled by long-term misuse of opioids are stabilised. 
On establishing the correct daily dosing regimen of methadone, tolerance is not 
established to the critical benefits of methadone, which are, inhibition of opioid 
withdrawal and deterrence of drug desire. As a result, regular, continuous doses 
may be used for years to treat OUD effectively. (79) As a result of these findings, 
OAT has proven to have hugely positive results in respect to retaining individuals 
in treatment, reducing opioid use, decreasing recounted hazardous behaviours, and 
minimising drug-related morbidity and mortality statistics.  
Typically in Europe, specialist outpatient centres account for the single largest 
supplier of OAT in terms of registered individuals. The second leading provider 
of OAT is primary health care centres. General Practitioners are employed in both 
settings to prescribe OAT. The pharmacology of OAT is subdivided into full or 
partial agonist. Complete agonists, such as methadone, attach to the mu opioid 
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receptor producing a dose-reliant upsurge in physiological effects. Partial 
agonists, such as buprenorphine, bind to the receptor but even at full saturation 
exercise less influence than that achieved by full agonists. In both settings, 
methadone is the most frequently prescribed opioid agonist treatment, where 
almost two-thirds (63 %) of OUD individuals in Europe receive it. (80) A further 
35 % of individuals receive buprenorphine, which is the principle drug treatment 
in the following eight countries: Croatia, Sweden, France, Norway, Finland, 
Czech Republic, Greece, and Cyprus. In Ireland, buprenorphine-naloxone 
(buprenorphine/naloxone) is presently only obtainable on a restricted named 
patient basis (81) although this is currently expanding. 
1.9 OUD in Ireland 
The most recent estimate of opioid misuse dates to 2014 when a “four-source 
capture-recapture method” accounted for 18, 988 opioid users (6.18 per 1 000 
population aged 15-64 years) in Ireland. (82) In 2006 less than one third of opioid 
users were 35years or older. However, in this more recent 2014 study, greater than 
half were, suggesting a definite ageing effect in this cohort, which is in line with 
European findings. The data was collected over a four-year period (2011-2014), 
allowing opioid use prevalence estimates for 2014 to be compared with estimates 
from 2011, 2012, and 2013. There was an increase each year, rising from 17,387 
in 2011 to 18,988 in 2014. (83) Data from the Irish drug treatment facilities 
suggest that opioids (mainly heroin) are the most common main drug of 
dependence amongst those commencing treatment. (82) 
The Health Service Executive (HSE), which governs Ireland’s public health 
division, oversees the provision of all publicly financed drug treatment. Its 
Primary Care Division oversees all drug treatment facilities, including OUD. It 
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also manages a number of national care groups. From a treatment perspective, 
Ireland mirrors the current European structure.  Methadone is the most commonly 
prescribed opioid agonist drug, which has been available in Ireland since the 
1980’s. The 1998 legislation, the Misuse of Drugs (Supervision of Prescription 
and Supply of Methadone) Regulations, implemented a specific administrative 
structure designed to monitor treatment delivery and patient trends, the 
confidential Central Treatment List (CTL). The legislation also enforced a 
protocol for the prescribing of methadone, the Methadone Treatment Protocol, 
which provides for the delivery of methadone treatment in the Irish context. As in 
Europe, in Ireland, under this legislation, methadone is provided for in both 
specialist outpatient centres and in Primary Care Centres, both chiefly staffed by 
General Practitioners (GPs). At year-end 2017, the total number of individuals in 
Ireland receiving Methadone was 10,316 of which 9,695 were in the community 
and 621 were in prison. Eighty HSE specialist outpatient centres providing OAT 
were in operation. Across both the clinics and the GP community setting, 362 GPs 
delivered the Irish service. (84) 
1.9.1 The Irish Management of OUD 
Launched in 2017, Ireland’s national drug strategy, ‘Reducing harm, supporting 
recovery: a health-led response to drug and alcohol use in Ireland 2017-2025’, is 
the third consecutive long-term drug policy and strategy document adopted in the 
country. (85) Its main aim is to curtail the ill effects resulting from the misuse of 
substances by empowering people with drug use disorders to access appropriate, 
tailored treatment. It also wishes to fulfil its aim by reducing overall mortality 
rates associated with drug misuse and abuse. (85) The strategy aims to promote ‘a 
healthier and safer Ireland, where public health and safety is protected and the 
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harms caused to individuals, families and communities by substance misuse are 
reduced and every person affected by substance use is empowered to improve 
their health and wellbeing and quality of life’. Harm reduction underpins its 
philosophy as it aims to specifically, ‘minimise the harms caused by the use and 
misuse of substances’. (85) 
The Department of Health, run by the Minister for Health, has overall 
accountability for implementing the strategy. A Minister of State supports the 
Health Minister and is responsible for the strategy. The National Oversight 
Committee in turn supports the minister for health. This committee meets 
quarterly and benefits from statutory, community and voluntary representatives. 
The committee also includes representatives from academic and the Professional 
bodies, the ICGP and the College of Psychiatrists (CPI). A key voice at the table 
is the service user and also from the National Family Support Network. The NOC 
itself is supported by a standing sub-committee, which is chaired by a senior 
official at the Department of Health. This sub-committee convenes monthly to 
reinforce the implementation of the strategy, as well as assisting in ensuring 
coordination between relevant national, regional and local bodies.  The Drugs 
Policy Unit at the Department of Health is tasked with delivering impartial and 
informed analysis and guidance to the National Oversight Committee.  
At a sub-national level, local and regional Drug and Alcohol Task Forces 
(comprising statutory, community and voluntary representation) are accountable 
for tactical implementation of the strategy. The National Drugs Strategy 2001 – 
2008 endorsed the foundation of the Mid-West Regional Drugs Task Force 
(MWRDTF) to research, instigate, cultivate and oversee a co-ordinated response 
to illicit drug use in counties Clare, Limerick, North Tipperary and Limerick City. 
The ‘Health Service Executive Mid-West Limerick Drug and Alcohol Services’, 
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in which study 1 of this thesis was undertaken, falls in the geographical area of the 
MWRDTF, and are responsible for the clinical element of the service in that area.  
1.9.2 Harm Reduction Services in Ireland 
From an Irish perspective the available harm reduction services available are 
1. Opioid agonist therapies, (OATs), mainly methadone (OATM) but 
recently also buprenorphine/naloxone combination therapy 
2. Take Home Naloxone Programmes, THN Programmes 
3. Needle and Syringe Exchange Programmes 
4. Outreach support 
5. Supervised Injecting Facilities (in development phase) 
1.10 Overdose  
While individuals with an OUD are at risk of succumbing to an array of acute ills, 
drug overdose (OD) in this population is the most grave of these. New synthetic 
opioids are evolving as a detrimental hazard to individual and public health. Since 
2009, 38 novel opioids have been identified on the European marketplace - 13 of 
which were recorded for the first time in 2017. Of the 38 novel opioids, 28 were 
by-products of fentanyl, of which 10 were identified for the first time in 2017. 
(60) Fentanyl is approximately 50 times more potent than heroin and 100 times 
stronger than morphine. (86) As such, these newly synthesised opioids can be 
intensely intoxicating, with miniscule amounts adept at causing life-threatening 
poisoning from rapid, severe respiratory compromise. This brands them 
particularly treacherous, especially for naïve consumers.  
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Furthermore, fentanyl derivatives appear to be highly addictive with grave 
dependence-producing capabilities, which could exacerbate the public health and 
social difficulties frequently linked with OUD.  
Among European adults, OUD is a well-documented source of avoidable 
mortality. Overall mortality rates of high-risk drug users typically range from 1–2 
% per year. Most recent records show that in Europe, drug OD remains to be the 
main cause of mortality among high-risk drug users, with the majority of ODs 
being male (79 %).  Heroin or its metabolites are implicated in the majority of 
fatal ODs.  
It is important to emphasise three distinct sub-populations are at risk of opioid 
overdose; 1. Individuals with a chronic OUD; 2. Individuals experimenting with 
other drugs who inadvertently ingest opioids; 3. Individuals intentionally 
overdosing, intentional poisoning. This thesis focuses on the first sub-population, 
individuals with a chronic OUD where accessibility to the opioid reversal agent 
naloxone is of the upmost importance. 
Statistically, relative to their peers of the same gender and age, Europeans with an 
OUD are 5 to 10 times more likely to die. (60) Higher mortality rates among 
individuals with an OUD are predominantly associated with OD, but other 
grounds for mortality, circuitously related to drug use, such as incurable 
infections, calamities, violent incidences and poisonings, are also notable. Again, 
it is important to distinguish between accidental poisonings and intentional self-
poisoning in relation to opioid misuse. This thesis focuses on accidental 
poisonings in the context of OUD. The treatment of intentional self-poisoning 
would require psychiatric expertise.  
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In addition to the above ailments, chronic poor health, manifested by an 
accumulation of interlinked conditions is present. Longstanding respiratory, 
cardio-vascular and hepatic conditions are commonplace and explain some of the 
reasons for increased mortality among senior and seasoned misusers or opioids. 
(87) 
Statistics pertaining to OD, particularly the European aggregate, should be 
interpreted with caution. The reason being that some countries systematically 
under-report their figures while lengthy record-keeping procedures result in 
recording delays in others. As a result, yearly estimates reflect a conditional 
minimum number. From an age perspective, in the European Union (EU) between 
2012 and 2016, in all age groups above the age of 30, deaths due to OD increased. 
Fatalities in the over-50 age category enlarged by 55%. In comparison, life losses 
among those aged 30–49 increased by 25%.  
The increasing trend in the recorded number of ODs in the elderly population 
highlights the ageing effect on individuals with an OUD in Europe, who are at 
maximum jeopardy of fatal OD. Most recent figures reveal that greater than 40 
deaths per million population were recorded in eight northern European countries, 
with the highest rates reported in Estonia (132 per million). Ireland ranked fourth 
in the list with a death toll of 70 deaths per million. (60) 
The magnitude of OUD and the burden of the disease on the individual, their 
families, and society as a whole are undeniable. Reducing morbidity and mortality 
associated with OUD is a major public health challenge in Europe and 
unquestionably in Ireland. We need to improve our management of the disease if 
we are ever to kerb its spread and ultimately gain control of its harrowing effects. 
Prevalence estimates of OUD in Europe range from less than 1 to more than 8 
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cases per 1 000-population aged 15–64. (60) Ireland has one of the highest at 6.18 
per thousand-population aged 15—64 years (95% CI: 6.09—6.98). (88) Ireland’s 
drug-related deaths among adults (aged 15-64 years) are greater than three times 
the most recent European estimate. (82) 
Where methadone is the chief OAT prescribed in both Europe and Ireland, the 
medicine most effective bar none at reversing opioid OD is naloxone. Naloxone 
can reverse the depressant effects of opioids on the respiratory system both safely 
and effectively. It has a powerful affinity for opioid receptors, most notably μ 
receptors, and it works by challenging the opioid and displacing it from the 
receptor, thereby deactivating the receptor and reversing OD induced respiratory 
compromise. (89) Manufactured for the first time in the early 1960s, the Japanese 
company Sankyo applied for its patent, with a second tender submitted by 
Fishman and Lewenstein in New York in March 1961. (90) Naloxone was 
considered a more reliable and effective opioid antagonist with a better side effect 
profile than previously used drugs which resulted in it gaining regulatory 
endorsement from the US Food and Drug Administration (US FDA) for 
intravenous, intramuscular, and subcutaneous use. (89) Over the following 40 
years, subsequent research supplemented its safety profile by confirming that, 
even if inappropriately administered to opioid-naïve individuals, it does not cause 
harm (91) because in the absence of opioid antagonists, it exhibits essentially no 
pharmacological activity. Naloxone is most effective in reversing the effects of a 
heroin or a morphine OD, but of huge significance in the current opioid epidemic, 
it also works to reverse respiratory depression caused by other opioids, including 
fentanyl. (92) The World Health Organization endorses it and indeed methadone 
as an ‘essential medicine’.  
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The majority of ODs occur in the presence of others, and most ‘people who inject 
drugs’, PWIDs, have observed or have first-hand experience of an OD. Therefore, 
PWIDs, or their friends and family, are likely to be first on the scene to manage an 
OD emergency. (93) These familial and cordial networks, with suitable training, 
can be employed for medical intervention at an OD scenario with the very likely 
outcome of preventing death. WHO guidelines on the management of opioid OD 
in the community setting recommend improving the availability of naloxone 
among those who are likely to be bystanders at an opioid OD. (94) In order to 
make naloxone available where ODs occur, opioid OD prevention programmes 
train potential bystanders on how to recognise and respond to opioid OD and 
provide them with the medication. These so-called ‘take-home’ naloxone 
programmes (THNP) exist in Australia, Canada, Europe and the United States. 
(90, 95-97)  
From an Irish perspective, the Early Warning and Emerging Trends Committee of 
the Irish Health Research Board keeps up to date with European and national data 
sources of information to ensure Ireland is abreast of any significant 
developments.  In Ireland, an exclusive register retained by the Health Research 
Board, records the number of drug-related deaths, or as they refer to it, ‘drug-
induced deaths’. (98) This document, most recently published in 2017, tabulated 
the most up-to-date Irish figures which concern 2015, where the number of ‘all 
poisoning deaths’ were recorded as 348. Of these deaths, there were 252 
‘instances’ of opiates (includes heroin, methadone, morphine, codeine, 
unspecified opiate-type drug, other opiate analgesic) recorded as present in 209 
individual deaths. The majority of the deceased were male in their late 30s. Of the 
209 individual deaths, 84 were not alone at the time of death and the 
overwhelming majority, 185, did not occur in a public place. Both of these figures 
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support the need for THNPs. (99) Of the 209, 179 had two or more drugs 
implicated, most commonly benzodiazepines. Overall, the risk of early mortality 
from OUD, predominantly from an unintentional OD, trauma, suicide, or a 
communicable disease is increased by a factor of 20 from the average population. 
(100) Irish research supports the need to equip individuals with an OUD with the 
skills and education to prevent OD. (101) Ireland rolled out a national THN 






Chapter 2 Literature Review 
2.1 Chapter Overview  
This chapter focuses on the importance of harm reduction in combatting opioid 
dependence. A particular focus is shone on harm reduction programmes currently 
operating in Ireland. The chapter then reviews recent literature confirming the 
relapsing nature of opioid dependence and as such outlines the rationale for this 
thesis in optimising both MMTPs and THNPs. The chapter closes with the aims 
and objectives of the thesis itself.  
2.2 Harm Reduction 
The following section opens with a brief look at the increasing opioid epidemic 
and its toll on society. It will then define harm reduction. It will focus on one of 
the many grave illnesses associated with OUD, the spread of blood borne viruses, 
and the effective role harm reduction can play in kerbing their spread and as a 
result benefitting society hugely. Following a brief look at both the European and 
Irish current perspectives on harm reduction the chapter focuses on the four main 
harm reduction services currently available in Ireland with a final look at a 
potential fifth service, supervised injection sites, which should be up and running 
in Ireland shortly.  
2.2.1 Background 
Over the last 30 years, public opinion of opioid use has slowly begun to shift from 
the discussion of drug users as criminals with character flaws (103) to viewing 
drug dependence as a chronic brain disease. (104) Even with the positive 
initiatives and effective policy reform enacted thus far, the adverse toll OUD has 
on society endures. With the increasing accessibility to potent opioids—inclusive 
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of fentanyl and carfentanil— the opioid crisis is expanding. (105)  
Notwithstanding the encumbrance of opioid misuse on society is challenging to 
estimate, it is well recognised that the expenditures associated with OUD are 
extensive. (106) Social costs due to unemployment, criminal activity and violence 
all of which are inextricably connected with OUD, can result in crippling the 
economic budget. (107) Moreover, OUD is often linked with deprivation and 
social isolation. This can lead to acute and chronic illnesses both of which are 
costly to treat. (108) Therefore, it is understandable that harm reduction 
interventions have historically had low public support (109) because these 
strategies aim to reduce the harms of drug use but do not focus on eliminating 
drug use itself. (110)  
2.2.2 Defining Harm Reduction  
Harm reduction embraces interventions, programmes and policies that primarily 
endeavour to decrease the impact of the adverse health, social and financial 
ramifications of drug misuse without necessarily decreasing drug consumption. 
(111) Harm reduction strategies respect the individuals’ right to consume such 
substances. A central principle of harm reduction is to address the immediate 
health and social requirements of individuals with substance use disorders, 
particularly the socially marginalised, by offering a suite of services inclusive of 
Opioid Agonist Treatments, Take-Home Naloxone Programmes, Needle and 
Syringe Exchange Programmes, Outreach Services and Supervised Injection Sites. 
Recently, new opportunities for bettering the scope and usefulness of harm 
reduction strategies have come to the fore, especially through advances in the 
arena of information technology. Novel methods include, for example, engaging 
with e-health applications to convey brief interventions. (60) 
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2.2.3 Curtailing the spread of blood borne viruses  
Opioid harm reduction policies are hugely important as individuals with an OUD, 
particularly those who inject, are in danger of developing infectious diseases 
through the sharing of drug use paraphernalia. Intravenous drug use continues to 
play a dominant role in the spread of blood-borne infections such as the hepatitis 
C virus (HCV) and, in some countries, the human immunodeficiency virus (HIV). 
(112)  
Most recent European statistics indicate that at > 8 cases per million population, 
Ireland remains to have one of the largest number of newly diagnosed HIV cases 
because of injecting drug use. (112) Ominously, in 2016, half of the new HIV 
diagnoses due to drug injecting in the European were not diagnosed until the virus 
had already begun to impair the immune system. This ‘late HIV diagnosis’ results 
in delays in commencing anti-retroviral treatment which in turn increases patients’ 
morbidity and mortality. Timely diagnosis and commencement of anti-retroviral 
treatment offers those affected a normal life expectancy but this prospect is 
squandered with late diagnosis. (112) Early treatment also reduces the likelihood 
of cross contamination and transmission of the infection, which is of paramount 
importance among clusters with higher risk behaviours, such as people who inject 
drugs (PWIDs). 
In Europe, viral hepatitis, chiefly infection with the hepatitis C virus (HCV), is 
extremely prevalent among PWIDs. For every 100 people infected with HCV, 
untreated, 75 to 80 will develop chronic infection. (113) Worryingly, infected 
individuals often feel no obvious symptoms, and many are oblivious to their 
infection. As such it is often denoted the ‘hidden’ epidemic. (114) A devastating 
consequence is that chronic HCV infection, often exacerbated by heavy alcohol 
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consumption, will result in increased morbidity due to a greater number of cases 
of severe liver disease, including cirrhosis and cancer, among an ageing cohort of 
high-risk PWIDs which ultimately increases overall mortality rates. This places a 
major burden on healthcare systems. (114) 
HCV is more common among older PWIDs than among the younger generation, 
emphasizing the amassing risk over time, and the great encumbrance of infection 
among the ageing cohort.  
In Ireland, in 2016, PWIDs accounted for greater than one third of hepatitis C 
virus (HCV) cases. In line with Europe, old age (older than 34 years) was a 
noticeable characteristic of intravenous drug users among HCV notifications in 
Ireland. (82) As documented above, chronic HCV infection coupled with an 
ageing population implies that the number of cases of advanced liver disease will 
undoubtedly rise in the next decade placing an even greater toll on our already 
deplete health services. Yet HCV is both preventable and curable. (115) 
Irelands’ first national hepatitis C strategy 2011-2014 published in 2012 but had 
no financial provision for its enactment. (116) As a result, it was not until 2014, 
that the Government sanctioned the rollout of the ‘National Hepatitis C Treatment 
Programme for 2016-2026’. (117) The programme is staffed with a Programme 
Manager, who oversees operations and a Clinical Lead, who oversees the clinical 
aspect of the programme. In July 2017, comprehensive National Clinical 
Guidelines on screening for Hepatitis C were circulated in Ireland. HCV treatment 
is currently delivered through specialist services based in the acute hospital 
setting. Once clinically prioritised and referred by their doctors, PWIDs can also 
avail of this service. In 2018, on a trial basis, the HSE commenced offering HCV 
treatment in the specialised Methadone outpatient clinics to affected individuals in 
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opioid agonist treatment in order to maximise treatment coverage as experience 
had indicated a number of PWIDs were reluctant attendees at hospital based 
services. (117) 
Amongst PWIDs, hepatitis B virus (HBV) infection is less prevalent than HCV 
infection. In Ireland, from a HBV perspective, a descending trend in the number 
of notifications was noted between 2008 and 2014; however, recent data indicates 
that numbers of cases identified and reported upon are now stable. PWIDs are also 
at risk for contracting other infectious diseases, such as hepatitis A and wound 
botulism. (118) 
2.2.4 Increasing Mortality Rates  
However, immeasurable in monetary terms, the most expensive cost of the opioid 
epidemic is undoubtedly the associated loss of life. In 1993, the ‘European 
Monitoring Centre for Drugs and Drug Addiction’ (EMCDDA) was established. 
It provides the EU and its Member States with an accurate synopsis of European 
drug harms and a concrete evidence base to inform policymakers’ decisions on 
drug laws and strategies. It defines ‘drug-related death’ as a death unequivocally 
due to the consumption of illegal substances. Typically, these fatalities occur 
quickly post the ingestion of the drug and are therefore termed ‘directly caused by 
drugs’. In the United States and the increasingly in the EU the term applied is 
‘drug-induced deaths’. ‘Poisonings’ is the word used in the International 
Classification of Diseases or in nonprofessional references the term overdose 
(OD) is cited. (119)  
From a mortality perspective, latest statistics from the EMCDDA reflect that 
‘drug-related deaths’ in Europe have increased for the fourth successive year. 
(120)  Data from 30 countries, 28 EU and Turkey and Norway report an estimated 
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9,138 deaths have occurred in 2016 representing a 4% increase from 2015. As 
OUD is now a leading cause of death worldwide, it is the resultant loss of life that 
has helped gain more traction for harm reduction strategies in recent years (121) 
but society has still a long way to go before fully embracing them. 
2.3 Opioid Agonist Therapy  
OAT is currently the evidence based gold standard treatment option for 
individuals with an OUD, optimising their general well-being from a safety and 
overall physical health perspective. (122) For this reason, the World Health 
Organization lists the OAT, methadone on their register of essential medicinal 
products. (123) Evidence to defend the effectiveness of OAT is well documented 
in academic literature. Research shows it significantly reduces crime rates, 
increases employment and improves affected individuals’ social well-being. (124) 
OAT results in decreased rates of infectious diseases related to injection drug use. 
(125) A recent study in the BMJ showed retention in methadone treatment results 
in a considerable decline in the risk for all-cause mortality in individuals with an 
OUD. (126) 
In Ireland OAT is initially prescribed by befittingly trained specialist General 
Practitioners (GPs) with level 2 training. (127) Typically, this occurs in specialist 
OAT clinics or less frequently in the general practice setting, where GPs (at level 
2 training) with the appropriate expertise working in their own community 
practices initiate OAT. Once a patient’s dosing regimen is stabilised on OAT, and 
their overall care plan is optimised in the specialist setting their transfer to less 
experienced GPs (at level 1 training), working in community practices can occur. 
Here the patient can avail of ongoing maintenance management of their illness. 
50 
 
Training for GPs in relation to ‘opioid substitution prescribing’ is organised by the 
Irish College of General Practitioners in conjunction with the HSE. 
Studies from 2013 and 2016 show a generally optimistic attitude of prescribing 
GPs toward OATM treatment in Ireland. (128, 129) Prescribing GPs work 
diligently with both statutory and non-statutory bodies to ensure optimal provision 
of OAT. (81) 
As noted above, the pharmacology of OAT can be sub-divided into full agonist or 
partial agonist. Methadone, which is expanded upon below, is a synthetic full mu-
receptor agonist that is usually administered daily to patients for oral consumption 
to treat their OUD. (130) Buprenorphine is a partial mu-agonist that is 
administered sublingually. In both Europe and Ireland, methadone is the most 
common preparation prescribed. (80) In Ireland, the combination OAT 
buprenorphine-naloxone is presently only obtainable on a limited named patient 
basis. (81) Although this is expanding since the passing of legislation to include 
buprenorphine containing products in the treatment of opioid dependence in 
Ireland. (131) 
In the absence of a formal protocol, methadone was prescribed in Ireland from the 
early 1980s to certain vulnerable cohorts such as those diagnosed with HIV (132) 
and also pregnant women. (133) By the early 90’s, the availability of methadone 
on prescription was still limited to the capital, Dublin. To address the need for 
methadone to be available nationwide, in 1993, an ‘expert group’ undertook to 
publish a formal protocol for the prescribing of methadone nationally entitled, 
‘Report of the Expert Group on the Establishment of a Protocol for the 
Prescribing of Methadone’. On foot of this report, in 1998, the ‘Misuse of Drugs 
(Supervision of Prescription and Supply of Methadone) Regulations’ were 
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published which clearly outlined specific regulatory requirements for the 
prescribing of methadone. (134) Rolled out in 1998, the Methadone Treatment 
Programme (MTP) protocol guided OAT treatment delivery in Ireland, ensuring 
appropriate protocols for methadone prescribing, fitting standards for the 
management and support of clients, specialist-training prerequisites for GPs, and 
best practice procedures to undertake clinical audit. (134)  
Since its inception in 1998, several appraisals of the MTP have been performed, 
both internally in 2005 by the ‘Methadone Prescribing Implementation 
Committee’ itself and by external bodies in 2010. (135) All clients in receipt of 
methadone are registered on the confidential Central Treatment List (CTL). Each 
client is assigned one specific prescriber and a single pharmacist. The Irish 
College of General Practitioners (ICGP) delivers and oversees the specialist 
training for GPs to upskill and prescribe OAT. Since 1998, year on year, the tally 
of specially trained GPs has increased steadily. (84) The introduction of the 
scheme encouraged General Practitioners and pharmacists in community settings 
to become involved with the prescribing of OAT. (136) 
Originally unveiled as an analgesic in 1939 (137) methadone was first launched as 
a treatment option for opioid dependence by Dole, Nyswander, and Kreek in 
1964. (137, 138) The extended half-life of methadone results in a “narcotic 
blockade” which eradicates withdrawal symptoms for up to 36 hours. Given in 
appropriate doses, it also moderates opioid craving (139) and in doing so frees the 
client from the daily cycle of searching for, purchasing, and consuming illicit 
opioids. (140) 
In 2017, the regulation S.I. No. 522 replaced the 1998 Regulation S.I. No. 225. 
(131) The new regulation adds buprenorphine-containing products to the schedule 
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of products authorised for OAT in Ireland. As a result, individuals with a specific 
medical diagnosis, which results in methadone, being contraindicated or not 
suitable can now be offered an alternative OAT, in the form of a sublingual tablet, 
buprenorphine/naloxone. (141) As a partial agonist, buprenorphine has less 
sedating and euphoric effects than full agonists, such as methadone, do. Though a 
partial agonist, it does exhibit a high affinity for the µ receptor, binding more 
firmly to opioid receptors than other opioids or opioid antagonists. This allows it 
to block the effects of concurrently administered opioids, reducing the risk of 
relapse in buprenorphine maintained clients. (142) It has a bell-shaped dose-
response curve, and hence a long duration of activity which allows for less than 
daily dosing. (143) Naloxone does not diminish the efficacy of sublingual 
buprenorphine but its inclusion deters intravenous misuse of the drug (144) and 
hence the formulation of both buprenorphine and naloxone, is used in Ireland.  
Previous research in Ireland had identified buprenorphine injecting as a problem 
hence the combination product is the preferred product here. (145) Each 
sublingual tablet contains 2 mg buprenorphine (as hydrochloride) and 0.5 mg 
naloxone (as hydrochloride dihydrate). Buprenorphine/Naloxone when 
administered sublingually reaches peak concentration after 90 – 150 minutes. 
However, as in Europe, in Ireland the majority of OAT is methadone based and as 
such is the focus of this thesis. Opioid agonist treatment with methadone (OATM) 
has been validated as an effective treatment for opioid dependency by more than 
50 years of research (137) and today, Cochrane reviews show robust evidence to 
support its use. (146, 147) 
Internationally, significant qualitative research with respect to individuals’ 
perspectives of a MMTP has been published. Much research has been done 
focusing on ‘out-of-treatment’ individuals (148) and on retaining individuals in 
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treatment (a significant predictor of outcome). (149) For those in treatment, 
qualitative studies focusing on individuals’ access to treatment (150), level of 
influence on their treatment plan(151) , quality of life (152) and their overall 
satisfaction in methadone treatment (153) are well documented. Similarly, in 
Ireland, qualitative studies attempting to address issues with OATM from the 
perspective of the Individual have been undertaken. (154-156) 
However, both internationally and nationally, very few, if any, of these studies 
focus on the most complex of individuals, those who remain entrenched in the 
specialist system, for whom the service appears to fail, as they never progress to 
the community setting for treatment. The Methadone protocol in Ireland 
advocates for OAT to be delivered ideally by the patient’s community GP but 
some patients never attain this goal. To date, no Irish study has specifically 
investigated this cohort. This thesis, in researching their individual journeys, 
hopes to establish patterns of similarity in their lives, which would flag their high-
risk status on admission to OAT and allow all relevant services to collectively 
intervene appropriately and optimise their individual care plan sooner. 
2.4 Take Home Naloxone Programmes 
In 2015, the EMCDDA conducted a systematic review of 21 studies on ‘take-
home naloxone’. This review confirmed that knowledge acquisition on the 
appropriate management and administration of naloxone by individuals with an 
OUD and their peers improved dramatically with appropriate education and 
participation in training courses, which had the resultant benefit of decreasing the 
‘drug-related death’ rates. (157) 
THNPs target three specific populations: individuals with OUD, their carers 
(inclusive of peers and familial relations) and employees in agencies likely to 
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interact with opioid users, such as staff of MMTPs. Therefore, in the event of an 
opioid OD, where medically indicated, naloxone may be administered to the OD 
victim in advance of the arrival of the emergency services. Following naloxone 
administration by laypersons, the reported effectiveness of naloxone in reversing 
respiratory depression is as high as 75–100%. (96) As such, evidence confirms 
THNPs should be considered effective in reducing the death toll associated with 
opioid OD. (158) 
Initially introduced in pilot format, today, universally, a broad range of THNPs is 
today.  The diversity in the individual programmes reflects the need to modify 
each programme to the available assets, local environment and most importantly, 
each individual country’s regulations on the supply and use of naloxone. 
However, worldwide, practical and regulatory hurdles have hampered the 
adoption of take-home naloxone programmes, particularly because naloxone must 
be pre-prescribed by a doctor directly to the person for whom it was intended. In 
response to a strong increase in the number of opioid overdoses, worldwide, 
solutions have been found to facilitate increased access to naloxone inclusive of 
its legal recognition as an emergency medication (Ireland, United Kingdom, 
Italy), repeal of prescription restrictions (Australia, Canada, France and several 
US states), and local and temporary legal exemptions for THNPs (Denmark, 
Norway). 
Another huge step forward in making naloxone more accessible was its recent 
approval as a nasal spray as up until the very recent past, available products were 
solely destined for parenteral use. However, extensive research on its 
pharmacokinetics proved that naloxone is sufficiently absorbed through the nasal 
mucosa to exert an antagonist effect upon opioids, which have caused the 
symptoms of overdose. (159) As a result, in November 2015, Narcan Nasal Spray 
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was launched by Adapt Pharma and became the first USFDA non-injectable 
naloxone product for the treatment of opioid OD to be sanctioned. This new 
intranasal route of administration was considered relevant for use by laypersons 
and non-medical responders in community-based programmes. In July 2017, 
following a 12-month trial, France became the first European country to authorise 
the marketing of a nasal naloxone spray. In November 2017, the European 
Commission granted authorisation for the marketing of an intranasal product 
across the European Economic Area, which in addition to the European Union 
includes Iceland, Lichtenstein and Norway. With increasing implementation of 
THNPs, the evidence base as to their effectiveness is growing. (160)  
Ireland rolled out a national THN Programme in October 2015, following a short 
pilot exercise. In its current format, opioid users, their peers, familial members, 
carers and relevant agency employees agreeable to partake in the programme must 
attend a video-based teaching session and pass a post-training test questionnaire. 
Training, approved by the Pharmaceutical Society of Ireland and the Irish Institute 
of Pharmacy, respects and obeys the ‘instructions for naloxone administration’ as 
listed in its ‘Summary of Product Characteristics’ (SmPC). If opioid users can 
demonstrate sufficient understanding of opioid OD signs, emergency management 
(calling an ambulance, basic life support and recovery position), and naloxone 
administration they are issued a take-home naloxone kit by prescription (102) as 
in Ireland, naloxone still remains a prescription only medicine.  
However, in a move to embrace laypersons’ trained skills in opioid reversal, 
Ireland now legally recognises naloxone as an emergency medicine. Therefore, 
legislation, passed in Ireland in 2015, allows for the emergency administration of 
naloxone by non-professionals who have completed an approved course of 
training in its use, without the need for a prescription. Entitled, ‘S.I No. 449/2015 
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- Medicinal Products (Prescription and Control of Supply) (Amendment) (No. 2) 
Regulations 2015’, this legislation allows for the procurement and administration 
of naloxone in an emergency. Since 2015, injectable naloxone has been available 
for community use in Ireland in a 2ml pre-filled graduated syringe. One dose is 
0.4ml, thus, each syringe has a maximum of five individual doses. In line with 
current training, one may repeat the dose of 0.4ml every 2-3minutes until the 
contents of the syringe are deplete. Its intended use is in the home or other non-
medical settings. Post administration, each use should be reported to the ‘Chief 
Pharmacist, Addiction Services, Health Service Executive’, who leads and 
manages the THN Programme and has overall responsibility for procurement and 
replenishment of supply.  
Intranasal naloxone was first launched in Ireland in August 2018 and is currently 
being rolled out nationally under the tradename nyxoid. The recommended dose is 
1.8 mg administered into one nostril (one nasal spray). In some cases, further 
doses may be necessary. The appropriate maximum dose of nyxoid is situation 
specific. If the patient does not respond, a second dose should be administered 
after 2-3 minutes. If the patient responds to the first administration but then 
relapses into respiratory depression, a second dose should be administered 
immediately. Further doses (if available) should be administered in alternate 
nostrils and the patient should be monitored whilst awaiting arrival of the 
emergency services.  
As noted above, no independent adverse effects are associated with naloxone. 
However, it can trigger an acute withdrawal syndrome if administered to a person 
whose μ receptors are pre-saturated with opioids. (89) Opioid withdrawal 
symptoms may consist of nausea, gastric spasms, muscle stiffness, muscle 
spasms/jerking, pains and discomforts, restlessness, retching, perspiring, 
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tachycardia, hyperventilation, hypertension, quivering and aggressive behaviour. 
(161) These symptoms occur in varying proportions and to varying degrees 
dependent on the dose of naloxone and the degree and type of opioid dependence.  
Naloxone has a relatively short half-life and as such with emerging new synthetic 
opioids, repeated doses, often in the hospital setting, may be necessary for the 
effective reversal of opioid induced respiratory depression. (162) One-quarter 
(163) to almost one-third (164) of opioid ODs need repeat doses of naloxone to 
avoid ‘recurrent opioid toxicity’. As such, transfer to hospital, post naloxone 
administration in the community, is hugely advisable to monitor both the 
withdrawal symptoms and to treat potential recurrent opioid toxicity.  
2.5 Needle and Syringe Exchange Programme 
These programmes allow intravenous drug users to access sterile syringes and 
appropriately dispose of used syringes in the community setting safely. Evidence 
shows these programmes reduce infectious disease rates arising from the 
hazardous and risky sharing of needles. (165) In Ireland, the programmes play a 
pivotal role in the delivery of harm-reduction services. Three differing programme 
models exist: ‘fixed-site’ services, ‘outreach syringe’ facilities and ‘pharmacy-
based’ programmes. All models typically provide a suite of sterile injecting 
paraphernalia, inclusive of varying sizes and brands of both needles and syringes, 
sterile swabs, and citric or acetic acid. Condoms, sterile disposable cookers, non-
toxic foil (for smoking heroin) and tourniquets are also obtainable.  
The ‘pharmacy-based’ programmes commenced in 2011. They have grown to 
expand substantially and today, apart from counties Dublin, Kildare and Wicklow, 
which are well serviced by both ‘fixed-site’ and ‘outreach syringe’ facilities, all 
remaining counties partake of their services. They dispense packages containing 
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the necessary injecting apparatus for either 3 or 10 sterile uses. By year-end 2017, 
111 pharmacies nationwide provided needle exchange facilities, and on a monthly 
basis in 2018, approximately 1,760 individuals availed of the service. (80) In 
areas without ‘outreach syringe’ facilities, pharmacy employees aid the 
dissemination of injecting paraphernalia with ‘backpacking’, a system whereby 
injecting material is distributed by staff directly to known individuals with a SUD.  
Regular audit and review of existing programmes are essential to maintain 
standards and improve outcomes, such as a review of the Irish needle and syringe 
programme. Published in 2015, results confirmed that the ‘pharmacy-based’ 
programme was performing well overall but it identified the need to for standard 
setting in the censoring of services delivered, to augment the uptake of testing for 
blood-borne infections, perhaps by offering in-pharmacy testing. Vaccination 
rates also needed to be increased. (166) Further recommendations were to increase 
the competence of pharmacy staff in giving harm reduction advice and support, 
and most importantly to reduce stigma. (166) 
2.6 Outreach Services  
These services connect individuals with drug use disorders with relevant harm 
reduction facilities. The ethos underlying outreach work is that individuals are 
‘out there' abusing substances and not aware or in contact with facilities which 
could help them better manage their illness. Particularly vulnerable are society’s 
youth who often engage in 'chaotic drug use', those who are homeless and those 
participating in the sex trade. Outreach services prioritize 'hard to reach' and 
'hidden' individuals. (167). In Ireland, the type of outreach work may be mobile or 
grounded in one location, domiciliary or community/street based, but always 
incorporates harm reduction approaches. The service also catalogues the number 
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of new clients registered each month, the number of clients who remain in contact 
with outreach services extending greater than three months and the number of 
clients who referred on a monthly basis to other services. This information is 
critical in gaining knowledge on the most marginalised of individuals in Irish 
society. (80) 
2.7 Supervised Injecting Facilities  
This service provides legal medical supervision to individuals wishing to inject 
previously purchased opioids or other drugs. Research shows that these facilities 
reduce the incidence of injecting rates in public, decrease the incidence of drug-
related communicable infections and lessen the overall drug-induced mortality 
rate. (168, 169) Internationally, public support is better (170) than previously 
recorded. (171) Approximately 90 supervised injecting facilities (SIFs) operate 
worldwide. Seventy-eight of these facilities are up and running in six EU 
Countries (Denmark, Spain, Germany, France, Luxembourg, Netherlands) and 
Norway. (120) Their objective is to not only reduce the consumption of drugs 
publically but more importantly to access marginalised, chaotic individuals with a 
drug disorder to lessen their high risk of contracting blood borne illnesses and 
death. (172)  
From a public use perspective, a reduction in the occurrence of public injecting 
with an associated decrease in drug related debris is evident. Most impressively, 
no escalation in drug abuse or in drug-related criminal activity has been seen. 
(173)  
By providing a secure, sheltered environment, guidance on safer injecting 
techniques and medical supervision prepared for the treatment of drug OD SIFs 
significantly lessen drug related morbidity and mortality. In overseeing millions 
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of injections, not one fatality has occurred in the facilities. Evidence from robust 
studies documents that by connecting clients to a wider network of care their 
access to health and social services increases, further improving their overall 
quality of life. (120) 
Currently, Irish law distinguishes between drug ‘possession for personal use’ and 
‘possession for sale or supply’. Consequences for ‘possession for personal use’ 
are contingent upon the category of drug and on the harshness of the penal 
proceedings, that is, whether a summary conviction or a conviction on indictment 
is sought. Regardless of the severity, the Criminal Justice (Community Service) 
Act 2011 necessitates that courts contemplate imposing a ‘community service 
order’ instead of a custodial sentence in all scenarios where up to 12 months’ 
incarceration might have been sanctioned.  
In May 2017 the Minister for Health Simon Harris and the Minister of State for 
Communities and the National Drugs Strategy, Catherine Byrne supervised the 
enactment of the ‘Misuse of Drugs’ (Supervised Injecting Facilities) Bill 2017’.  
The Bill allows the first supervised injecting facility in Ireland to be opened. It 
provides an exemption for licensed providers to allow clients to possess or prepare 
controlled substances for personal use in its premises. When in the facility, clients 
are exempt from legal proceedings in relation to personal drug possession or 
consumption, regardless of the drug category. Ownership of controlled drugs will 
remain to be an offence outside of the SIFs. Possession for sale or supply will 
remain to be illegal both inside and outside a SIF.  
2.3 Thesis Rationale  
Due consideration must be given to the fact that even the most advanced 
approaches in harm reduction techniques cannot fully tackle the unforgiving, 
61 
 
relapsing nature of drug use which is currently entrenched in the chronic lifecycle 
of drug dependency. (3) Since as far back as the early 90’s laboratory studies have 
shown that being in contact with particular ‘stressors’ escalates drug desire, as 
documented by subjective self-reporting. (174) Ecological momentary assessment 
(EMA) techniques are well established in assessing the association of both daily 
stressors and negative moods with drug use in the real world. A decade ago, the 
first study to employ EMA to assess the direct effects of stress and negative affect 
on day-to-day opioid use in the real world setting showed a positive correlation 
between them. (175) at the same time, the importance of neuroimaging in 
assessing relapse was making a break through. Imaging studies testing prefrontal 
executive functions, inclusive of restraining impulsivity and judgement showed 
significant deficits and decreased responses in the pre-frontal cortex of individuals 
with a SUD as compared with the control group. (176, 177). More recently, 
research has proven that cue-induced cravings for opioids stimulate specific areas 
of the prefrontal cortex, amygdala, hippocampus, insula, and ventral tegmental 
area. (178) A most recent 2018 publication showed that a ‘sensitised reward 
response’, ‘strong stress-reactivity’, fused with ‘impulsivity’ are all likely to 
increase the likelihood of relapse (179), as do other neuro-cognitive correlates of 
drug dependency such as poor insight (180), and reduced capacity for voluntary 
choice. (181, 182) A second 2018-publication shows relapse is linked to drug-
related prompts such as locations of drug use, drug equipment, the drug itself, or 
anxiety/trauma, emphasizing the critical role memory plays in drug relapse. (183) 
Accordingly, OAT is the preferred option for many. It is imperative, therefore, in 
the treatment of OUD that MMTPs serve their clients optimally.  
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Secondly, the effectiveness of THNPs in reducing mortality rates in opioid 
overdose is well researched. Put simply, they work. Therefore, it is crucial to 
maximise their effectiveness.  
2.4 Thesis Aims and Objectives 
The first study in this thesis is an in-depth qualitative study, which undertakes to 
determine why the HSE’s methadone maintenance treatment programme (MMTP) 
situated in Limerick City, in the Mid-West of Ireland fails to work for a cohort of 
Irish OUD individuals. These individuals are likely the most complex of OUD 
individuals in treatment. This thesis aim to empower them to voice their personal 
experiences of their journey to and through the MMTP. Secondly, it would be a 
failing of this thesis not to address the most emotive and difficult of outcomes for 
persons with an OUD, opioid OD. In line with the aim of our drug strategy, ‘to 
reduce mortality rates associated with drug abuse’, this thesis aims to enhance 
our understanding of the newly established Irish Take Home Naloxone 
Programme (THNP), to ensure it is functioning optimally in its campaign against 
OD.  
2.4.1 Aim Study 1 
To establish the barriers to progressing through a Methadone Maintenance 
Treatment Programme (MMTP) by exploring the perspectives of the individuals 
in Ireland’s ‘Health Service Executive Mid-West Limerick Drug and Alcohol 
Services’ 
2.4.2 Objectives Study 1  
1. To understand from the perspectives of persons with lived experience of 
OUD a) how they came to develop an OUD, b) why the current 
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programme is not working for them, and c) what they propose that would 
be more effective.   
2. To co-develop with people with lived experience innovative approaches to 
addressing OUD in ways that are more acceptable to clients and therefore 
more likely to have greater uptake on effectiveness. 
2.4.3 Aim Study 2 
To optimise Ireland’s national Take Home Naloxone Programme  
2.4.4 Objectives Study 2  
1. To conduct an in-depth review of Ireland’s THNP  
2. To analyse which variables most significantly impact on a person’s 
hospital attendance post naloxone administration, a factor known to 
improve overall survival rates in the management of opioid overdose 
OUD individuals themselves narrate this thesis. Documenting their voice in 
addressing the complexities of OUD is ultimately, what will determine our 
success in combatting the adverse outcomes of OUD. Secondly, shining a focus 
on the Irish THNP gives us an appreciation of its effectiveness and highlights 
potential means to better its overall efficacy particularly in relation to hospital 
attendance, a key necessary factor in the management of OD and thus ensuring the 
voice of OUD individuals is not lost to a premature death.  
2.5 Chapter Conclusion  
The opioid crisis is a multifaceted, complex issue (184) and individuals with an 
OUD continue to be highly stigmatized in society. (154) Poverty, mental health 
illness, and resultant social exclusion are inextricably enmeshed in the opioid 
scourge. (185) Low socioeconomic status, homelessness, and incarceration also 
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play a pivotal role in perpetuating the opioid crisis. (186) As such, individuals 
with an OUD often find it impossible to achieve abstinence and escape their drug 
dependence. Treatments based on the philosophy of harm reduction, which 
minimise the risks associated with their illness, as opposed to treatment options 
based on abstinence, are often the most effective and suitable treatment. The 
association between opioid dependence and the above social determinants of 
health is essential to emphasise, as relevant policy makers must give appropriate 
recognition to the benefits of employing a harm reduction strategy. (185)  
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Chapter 3 Methodology 
3.1 Chapter Overview  
This chapter opens with a brief explanation as to why both the ontological and 
epistemological perspectives underlying the philosophy of this thesis are 
important and subsequently they are described in detail. Two studies underpin this 
thesis and the methodological approaches undertaken in both are then examined. 
Study 1 is a qualitative study, study 2 a quantitative one. As such, this thesis 
employs a mixed method study design. Qualitative data allows for the “voice” of 
the participants to be heard and interpretation of observations. On the other hand, 
the quantitative data in study 2 includes closed-end information that undergoes 
statistical analysis and results in a numerical representation. (187) As study 1 is a 
qualitative study the phenomenological perspective underpinning its methodology 
is first defined and subsequently the studies overall design, setting, sample size, 
and the methods for both collecting and analysing its data is documented. The 
latter half of the chapter focuses on the quantitative study in this thesis. This study 
was a cross sectional study reviewing the ‘Irish National Naloxone Database’. 
Initially variables were extracted from the database for descriptive analytical 
purposes. Subsequently, statistical analysis was undertaken to determine which of 
these variables, if any, influence a patient’s hospital attendance post naloxone 
administration in the OD setting.  
3.2 Theoretical Framework 
Philosophy provides the field of social sciences with the broad ideologies 
underpinning theoretical thinking (188) of which two main branches exist. The 
first branch is ontology, which in essence is the ‘study of being’, what actually 
exists in the world. The second branch is epistemology, which fundamentally is 
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the ‘study of knowledge’. Philosophy differentiates between ‘being’ and 
‘thinking’. Ontology and epistemology are inextricably connected with one other 
and, according to some, are indivisible: ‘to talk of meaning is to talk of meaningful 
reality’. (189)  
The philosophical perspective underpinning this thesis reveals the assumptions 
that were made about the research, leading to choices that ultimately informed the 
rationale, outline, methodology, and methods of the thesis, as well as analyzing, 
interpreting and summarizing its findings. As such, it is crucial to outline its 
philosophical basis.  
3.2.1 Ontological Perspective 
Ontological perspectives range from ‘realists’ to ‘idealists’. Realist ontology 
believes in the presence of one solitary ‘reality’, which can be examined, 
interpreted and experienced as a ‘truth’. A confidence that the ‘real’ world exists 
autonomous of human experience. Contrastingly, in idealist ontology it is 
supposed that ‘reality’ is fabricated within the human psyche, such that there is no 
one ‘true reality’. Reality is ‘relative’ depending on the individual experience at 
any given period and location. The external world has no independent existence 
from our thoughts, language and representations. (190) Constrained idealists, such 
as I, believe, the existence of an external world places both ‘constraints and 
opportunities on the reality constructing activities of social actors, but regard 
social constructions as having a high level of autonomy from it’. (190) In other 
words, social interactions influence our perception of reality but the external 
physical world influences our experience of this reality. It is this ontological 
philosophy, which frames this thesis.  
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3.2.2 Epistemological Perspective 
Epistemology encompasses all features of the legitimacy, possibility and means of 
knowledge acquisition. It is notable because it shapes how academics structure 
their research in their attempts to uncover truths. Epistemological viewpoints 
range from ‘objectivists’ to ‘constructionists.’ Objectivist epistemology adopts the 
belief that reality lives outside, or ‘independently’, of the individual brain. 
Objectivist research is useful in providing consistent, external validity. 
Constructionist epistemology refutes the concept that objective ‘truth’ exists and 
is lingering ‘out-there’, awaiting discovery. As an alternative, ‘truth’, or sense, 
unfolds from our interaction with the ‘realities’ in our biosphere. Constructionist 
research gives context specific meaning to a subject or issue. The term social 
constructionism, coined by Blaikie, merges both views. That is to say, ‘knowledge 
is neither discovered from an external reality nor produced by reason 
independently of such a reality. It is the outcome of people having to make sense 
of their encounters with the physical world and with other people.’ (190) This is 
my epistemological positioning and the one on which this thesis is constructed.  
Originating from ontology and epistemology are philosophical viewpoints. These 
viewpoints shape our beliefs that then ultimately influence our actions. (191) At 
either end of the philosophical spectrum lie positivism and interpretivism. 
Positivism takes an impartial, objective view, which relies on specifics and 
tangible data. It is a philosophy, which accepts only things that can be seen or 
proved. (192) Conversely, interpretivism, accounts for individual, personal human 
pursuits and emphasises meaningful interpretation rather than hard data. 
Interpretivism aligns with the philosophical position of idealism, and refutes the 
positivist view that meaning resides within the world independently of 
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consciousness. (192) According to the interpretivist approach, it is important for 
the researcher to appreciate differences between people (193) and as such 
underlies my philosophical perspective.  
Two studies underpin the research of this thesis. This section will first review the 
methodological approach of study 1 and subsequently outline the methodological 
approach of study 2.  
3.3 Study 1, Qualitative Study 
‘Barriers to progressing through a Methadone Maintenance Treatment 
Programme: Perspectives of the Individuals in Ireland’s ‘Health Service 
Executive Mid-West Limerick Drug and Alcohol Services’ 
3.3.1 Study 1 Phenomenological Perspective  
Within the perspective of interpretivism lies the methodological approach of 
phenomenology. The rationale of this approach is to pinpoint ‘phenomena’ 
through the lens of the research participants. This typically results in the 
researcher assembling ‘profound’ insights and observations through inductive, 
qualitative methods. The researcher then presents it from the viewpoint of the 
research participants. (194) 
Epistemologically, phenomenological methods embrace the personal knowledge 
and subjectivity of each participant, and highlight the significance of their peculiar 
viewpoint and individual interpretation. The methods strategically gain insights 
into participants’ drives. (194)  
Pure phenomenological enquiries aim fundamentally to define rather than explain, 
and to commence from a standpoint free from theories or prejudices. (195) Lately, 
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researchers have contested the ability of a researcher undertaking a study ‘free 
from preconceptions or biases’.  
Instead, they highlight the significance of the researcher stating clearly how the 
findings in their study have been interpreted and understood. The researcher is 
discernible in the ‘frame’ of the study as an attentive, independent player rather 
than an isolated and removed observer. (196) This approach is particularly 
effective at supplementing the research with an interpretative element allowing it 
to have practical applicability to inform, support or challenge policy and action. 
This is the phenomenological approach underpinning Study 1.  
3.3.2 Study 1 Design  
The goal of the research undertaken in study 1 is to understand better why the 
programme failed to work as expected in this patient population. It describes the 
‘lived experience’ of chronic opioid users in receipt of long-term methadone 
treatment in Ireland’s HSE Mid-West Limerick Drug and Alcohol Services. It is a 
qualitative analysis of narrative data. In essence, the emphasis is on meaning, 
understanding the realities of developing and sustaining an OUD while in receipt 
of methadone.  
3.3.3 Study 1 Participants and Setting 
At year- end 2016, 134 individuals were receiving treatment with the opioid 
agonist, methadone, in the Specialist Drug and Alcohol Treatment Programme, 
Slainte, based in the HSE Mid-West Limerick Drug and Alcohol Services.  Of 
these 134 individuals, only 20 (15%) transferred to the lower risk, GP setting in 
the community (197).  
Slainte operates 10 methadone clinics weekly. Each clinic monitors approximately 
14 clients. Clients are randomly assigned to their assigned clinic. I oversee three 
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of these clinics, resulting in an average exposure to 40 clients weekly, with a male 
to female ratio of 3:1. Therefore, this client exposure reflects a good 
representative sample of the overall population of the clinic.  
Trust was integral to achieving an honest account of each individual’s lived 
experience. I had worked closely and built a good rapport with all individuals over 
the preceding two years.  I compiled an information sheet, incorporating all-
important details of the study.  As many of the potential participants were illiterate 
or had only very basic literacy skills, I verbally explained the information leaflet 
to them and asked them to bring it home where they could further review it with 
their families. After this information giving session, each potential participant was 
given an opportunity to think about his or her possible involvement and discuss 
the research with me as necessary. A minimum period of one week was allowed 
before following up and asking them if they were willing to sign the consent form. 
All individuals who were approached agreed to participate in the study. 
3.3.4 Study 1 Sample Size 
Qualitative research often employs ‘purposeful sampling’ to identify and select 
the most appropriate and informative of cases (198) that are particularly well-
informed or skillful in the subject matter. (199) In addition to knowledge and 
understanding, the importance of their readiness and disposition to partake, and 
their aptitude to communicate their experiences and attitudes in an eloquent, open, 
and reflective style is documented in the literature. (200) In contrast, random 
sampling is employed to minimise bias in recruitment and to allow for the 
potential influence of identified and unidentified variables (201) , safe guarding 
the generalizability of findings.  
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There exist numerous purposeful sampling designs. The design employed in study 
1 of this thesis is criterion-i. (198) The aim of this method is to pinpoint and select 
all instances that fulfil some predetermined condition. In this study, the inclusion 
criteria was that each individual had spent a minimum of two years on the MMTP, 
Slainte. As such, 24 of my clients were eligible for inclusion in the study, 
choosing those who had been longest on the programme first to participate. 
Qualitative methods chiefly emphasize saturation (i.e., procuring an in-depth 
appreciation by continuing to sample until no new essential information is 
attained). (202) Three main factors shaped this study’s optimum sample size, or 
‘saturation’, the depth of the data conveyed by the interviewees, the emergence of 
common themes during data analysis and the pragmatic restrictions I was working 
under, mainly time constraints. Considering this, 17 of the eligible 24 individuals 
were interviewed of which 13 were male and 4 were female, reflecting a male to 
female ratio similar to the overall population of the clinic, 3:1. The 17 participants 
had each spent on average 7.5 years engaging with the MMTP. 
3.3.5 Study 1 Data Collection 
Phenomenological based research can employ an array of methods to fulfil its 
needs inclusive but not limited to interviews, individual surveillance, focus groups 
and scrutiny of transcripts. 1:1 semi-structured interviewing was the method 
employed to collect data for this study. This data collection method enables the 
researcher and the participant to engage in a real time discussion. It also provides 
a forum for novel and unforeseen issues to arise, allowing the researcher to 
subsequently investigate issues in more detail with further questions should the 
need arise. ‘Minimum structure and maximum depth’ underpins the ethos of this 
method (194), where the researcher aims to balance maintaining a focus on the 
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research issues whilst avoiding undue influence over the individuals’ 
contributions.  
3.3.5.1 Interview guide 
In writing the interview questions, the authors were cognizant to safeguard 
participants’ ability to provide in-depth, complete accounts of their journey to and 
through the MMTP, Slainte. Six key factors (see below) framed the broad 
structure of the guide but ensured it was malleable enough to permit the 
interviewer to follow-up and further explore interesting foci as they appeared. The 
interviewer met with participants at a time that was most convenient for them. A 
reminder phone call to each individual was made 24hours before the scheduled 
time.   
3.3.5.2 Interviews 
I conducted individual comprehensive semi-structured interviews in a confidential 
office space situated in the HSE Mid-West Limerick Drug & Alcohol Services in 
Limerick City. At the outset, I explained the voluntary nature of the interview to 
each participant. Their choice to withdraw at any point and an explanation of how 
confidentiality was going to be upheld throughout was also clarified before both 
the participant and I signed the consent form.  
I opened the interview with an icebreaker and then inquired as to the individuals’: 
1) Childhood & Education, 2) Early Adulthood & Criminality, 3) Drug History 
prior to opioids, initiation of opioid use and current usage, 4) Current health, 
inclusive of mental health, 5) Current social circumstances (housing, employment, 
familial relationships), and 6) Engagement with MMTP (initial & current). The 
length of each interview varied, ranging from 10 to 47 minutes, with an average of 
24 minutes across the 17 interviews. There were no follow-up interviews. 
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3.3.5.3 Audio Recordings 
Individual names were purposely omitted from the recordings. The digital data 
was password protected before a professional transcribing company typed the 
recordings verbatim. An offer was extended to all participants to review their 
transcripts on their return but all declined this proposal.  
3.3.6  Study 1 Data Analysis 
Qualitative thematic analysis is a method for detecting, analysing, unifying and 
recounting themes found within a data set (203) and as such is a perfect fit for this 
study. The inductive thematic analysis of this study, presented below, was 
undertaken using the Braun and Clarke Structure of six levels of analysis. (203)  
Firstly, data familiarization and code generalization was completed. Then theme 
search, review and naming were carried out. An inductive analysis of the themes 
was subsequently undertaken. The overall process itself was both iterative and 
reflective and involved a continuous ebb and flow between the phases. Finally, a 




Table 3: Inductive Thematic Analysis of Study 1 
Phases Activity 
Phase 1  
Data 
Familiarisation  
This involved the main author, LM, reading the first transcript 
closely a number of times and checking the transcript back 
against the original audio recording for accuracy. Each review of 
the recordings provided some new understandings and LM began 
taking personal notes focusing on content, language use, context, 
and initial interpretative comments. 
Phase 2  
Initial Code 
Generalisation 
LM coded interesting features of the data using the computer 
software NVivo for qualitative data administration. LM worked 
methodically through the full data set. She gave complete and 
uniform consideration to each item, tagging and naming 
selections of text with each data item.  
Phase 3  
Theme search 
Merging and deviation of themes within the data were noted, 
leading to the development of the next phase, transforming codes 
into emergent themes. This involved LM working more with her 
notes rather than with the transcript and again inputting findings 
into the NVivo software package.  
Phase 4  
Theme review 
LM firstly ensured all coded data extracts formed a coherent 




LM scanned for links between emergent themes, assembling them 
according to conceptual similarities.  Each cluster was then 
allocated a descriptive label. Using NVivo allowed for short 
descriptions of themes and subthemes, using links to appropriate 
passages in the transcript.  
Phase 6 Final 
Report 





Subsequent to this initial assessment, a further sixteen interviews were 
undertaken. A similar analysis of the data from these interviews was conducted. 
Themes were reconfigured and re-labelled. Analysis of the 16th and 17th 
interviews revealed no new data and as a result, no additional interviews were 
deemed necessary as ‘saturation’ had been achieved. 
3.4 Study 2, Quantitative Study 
‘An in-depth review of Ireland’s Take Home Naloxone Programme’  
3.4.1 Study 2 Design 
Study 2 was a secondary data analysis on the ‘Irish National Naloxone Database’ 
from October 2015 to March 2018.  
3.4.2 Study 2 Setting   
In Ireland, training in the use of naloxone in the community incorporates an 
explanation on the need to complete an ‘incident report form’ post naloxone 
administration in the OD setting. Established in 2015, the ‘Irish National 
Naloxone Database’ (INND) processes these forms. This allows for the HSE to 
record data on the use of naloxone in community OD scenarios. Typically, staff of 
the homeless hostels, General Practitioners, staff of Methadone Maintenance 
Clinics, government employed key workers or peers/family members of OD 
victims trained in the use of naloxone in the community submit these forms. The 
data is recorded for each ‘Community Healthcare Organization’ in Ireland, of 
which there are nine. Community Healthcare Organisations (CHOs) divide the 
country into nine geographical boundaries, (see below) within which a broad 
range of community health services, inclusive of the Irish Drug and Alcohol 
Services, are delivered through the HSE and its funded agencies.  
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Area 1: Donegal, Sligo/Leitrim/West Cavan, and Cavan/Monaghan. Area 2: 
Galway, Roscommon, and Mayo. Area 3: Clare, Limerick, and North 
Tipperary/East Limerick. Area 4: Kerry, North Cork, North Lee, South Lee, and 
West Cork. Area 5: South Tipperary, Carlow/Kilkenny, Waterford, and Wexford. 
Area 6: Wicklow, Dun Laoghaire, and Dublin South East. Area 7: Kildare/West 
Wicklow, Dublin West, Dublin South City, and Dublin South West. Area 8: 
Laois/Offaly, Longford/Westmeath, Louth, and Meath. Area 9: Dublin North, 
Dublin North Central, and Dublin North West.  
3.4.3 Study Population   
The database recorded the following information, as shown in table 4, from 
October 2015 to June 2017. From June 2017 onwards, due to poor compliance in 
completing all sections of the form, variables highlighted in bold were no longer 
recorded, in the hope that a shorter form would entice a better response rate.  
Table 4: Study Population 
Details of person 
providing information 
Name  
Date of Birth  
Area of residence 
Date & place of where OD took place 




If receiving opioid agonist therapy 
Relationship to person providing information 
Substances involved (If known) 
Had the person injected heroin? 
Was the OD fatal? 
Details on ‘Sequence 
of Events’ 
Were you present when the person overdosed?  
If yes, how long did it take for them (from point of using) 
to overdose? If No, please provide reason 
What were the signs/symptoms of the OD? 
How many others were present? 
How many doses of naloxone were administered? 
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Was the ambulance called? If so, what information did 
you give the handler?  
Was CPR performed? If no, please provide reason 
Was the person who overdosed placed in the recovery 
position? If no, please provide reason 
Did you wait with the person who overdosed until help 
arrived?  
How long was it before the ambulance arrived? 
How long did you stay with the person who overdosed 
after the paramedics left?  
Did the person who overdosed attend hospital? If No, 
please provide reason 
Did the Gardai attend? Details of any action taken by the 
Gardai 
Was the used Naloxone Pack given to the ambulance 
crew? 
Additional Details Any additional information(including how person feels 
following incident) 
Was refresher training provided?  
Was a new naloxone kit re-issued?  
  
3.4.4 Study 2 Data Recruitment  
Initial review of the above data exposed that many variables were missing from 
the dataset. A more in-depth review of the reporting system in Ireland highlighted 
it to be quite onerous and not user friendly. From 2015-2017 the reporting process 
involved manually completing a lengthy form and then sending it by post or 
scanning it to the HSE.  Often these forms were misplaced by the recipient or 
incompletely or inaccurately filed out by the sender. To address this issue, the 
reporting system did change mid-way through 2017 to an electronic excel 
spreadsheet format, which is what is currently being used. Unfortunately, the 
excel sheet is also quite tedious to fill as the headings are unclear and the overall 
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format lacks structure or clear explanatory notes. As a result, many blanks and 
mistakes were evident at the time of review.  
3.4.4.1 Check Exercise 
To explore if, due to the onerous reporting mechanism, under-reporting of 
naloxone was a potential issue, a check exercise was completed on the recorded 
uses of naloxone in 2017 in hostels located in CHO areas 7 and 9. The main 
author telephoned all hostels in this catchment area who had submitted forms to 
the HSE on naloxone use in an OD setting and cross-matched their in-house 
recorded uses of naloxone against the HSE’s recorded number. In 2017, 53 uses 
of naloxone were documented. Of these, 37 uses were recorded in CHO areas 7 
and 9. Of the 37, 35 occurred in hostel accommodationacross the city of Dublin, 
which provide supported accommodation for those who find themselves 
homeless.  Results showed a measurable difference with hostel records recording 
54 uses of naloxone in 2017, a difference of 19 or a factor of 1.54 in comparison 
to HSE records.  
3.4.5 Study 2 Data Analysis 
Data analysis was essentially undertaken in a 2-step process. Step 1 was to 
tabulate specific data drawn from the database and undertake a subsequent 
descriptive analysis of the selected data.  Step 2 statistically analysed the data to 
ascertain what if any variables influenced a patient’s hospital attendance. Using an 
excel spreadsheet breakdown on the below listed variables was tabulated to get a 





Table 5: Variables extracted from the National Naloxone Database   
 Characteristics of Victim Characteristics of OD Setting 
1. Fatal or non-fatal. Where the OD occurred. 
2. Sex of the OD victim. Number of others present at the OD. 
3. Age of the OD victim. If an ambulance was called. 
4. If they were a registered 
Individual on a MMTP. 
The number of others present at the OD. 
5. If they had injected heroin 
at the time of the OD. 
If an ambulance was called. 
6.  Where relevant, how long it took the 
ambulance to arrive. 
7.  Where relevant, was basic life support 
administered. 
8.  The number of doses of naloxone 
administered. 
9.  Who administered the naloxone. 
10.  If the Gardai were present. 
11.  If the OD victim accompanied the 
ambulance team to the hospital setting. 
 
International literature indicates that a better understanding of the factors that 
influence whether a patient attends hospital or not post naloxone administration is 
important in the management of opioid OD. Therefore, the statistical analysis 
undertaken in this study undertook to determine which factors, if any, influenced a 
patient’s hospital attendance. The fact that the response variable in this study is 
binary (yes or no to hospital attendance) means that models suitable to conduct 
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the analysis include ‘Decision Tree’, ‘Random Forest Classifier’, and ‘Logistic 
Regression’.  
To generate a model comparison, the data was randomly spilt with 60% being 
used to train a decision tree, a logistic regression, and a random forest classifier. 
Twenty percent of the remaining data was then used to test the accuracy of each 
classifier, with the final 20% of data used as a validation set on the 'winning' 
model. This process was repeated 100 times. The results generated by the model 
comparisons are summarised in Table 6 below. 
Table 6: Model Comparison - Model wins and average accuracy 
Decision Tree Logistic Regression Random Forest Classifier  
19 42 39 
57.69% 65.06% 68.19% 
 
Although the random forest has a higher mean classification accuracy on the 
validation set (68%), the logistic regression model was most often chosen as the 
most accurate model (42 times). A logistic regression model also yields 
‘interpretable’ results, as opposed to the ‘blackbox’ random forest model. This 
allows the model to be inspected and potential inference to be derived from it.  A 
logistic regression model was chosen as the most appropriate to analyse the data.  
The statistical analysis in this paper was done using R and R-studio. (204, 205) 
The classification trees and random forest classifier were done using the 'r-part' 
and 'random-Forest' packages, respectfully (206, 207). The logistic regression 
model was calculated using the 'MASS' package, the ROC curve and 
classification analysis was done using the 'ROCR' package. (208, 209) 
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A logistic regression (LR) model was used to determine independent factors 
affecting a person’s attendance at hospital post naloxone administration. LR 
models the probability that a certain instance should be classified into a category.  
A LR model is of the form (1) where ρ is the probability of the event occurring. In 
this study, ρ is defined as the probability that a person will go to the hospital after 
an administration of naloxone.   
𝜌 =
exp⁡(𝛽0 + ⁡𝛽1𝑥1 + ⁡𝛽2𝑥2 +⋯+ ⁡𝛽𝑖𝑥𝑖⁡)
1 + exp⁡(𝛽0 + ⁡𝛽1𝑥1 + ⁡𝛽2𝑥2 +⋯+ ⁡𝛽𝑖𝑥𝑖)
 
          (1) 
 We can rearrange (1) to get: 
 𝐿𝑜𝑔𝑖𝑡(𝜌) = 𝐿𝑜𝑔 (
𝜌
1−𝜌
) = ⁡𝛽0 + ⁡𝛽1𝑥1 + ⁡𝛽2𝑥2 +⋯+ ⁡𝛽𝑖𝑥𝑖⁡   
(2) 
This is the log-Odds or logit model.  
In the results’ section of this study, section 5.4.3 the LR model coefficients are 
represented by 𝛽1, 𝛽2⁡𝑒𝑡𝑐.⁡in (2) above.  
 
It is much easier, however, to consider the Odds of an event instead of the log 




) = exp(𝛽0 + ⁡𝛽1𝑥1 + ⁡𝛽2𝑥2 +⋯+ ⁡𝛽𝑖𝑥𝑖)     
(3)  
This value can never be negative but may be larger than one.  
Finally, we consider the Odds Ratio, OR, to allow us to compare how strong each 












⁄         
(4)  
In the results’ section of this study, section 5.4.3.1 the interpretation of the odds 
ratio was derived using (4) above.  
3.5 Ethical Considerations  
Research on interviewing marginalised groups, such as those with an OUD, 
reflects on ethical considerations, the employment of incentives and the capability 
of research participants to provide informed consent. (210-212). Distressing life 
events such as abuse and abandonment often permeate their lives, (213) are shared 
during the interview and as such, the principle investigator must be cognisant of 
this at all stages of the research process. On an encouraging note, many 
participants view their contribution to research positively as it allows their voices 
to be heard which in turn might benefit others. (214)  Nevertheless, since 
qualitative research is dependent upon the disclosure of personal and sensitive 
information, clear and deliberate steps were taken to safeguard the self-worth and 
welfare of participating clients in Study 1 of this thesis.  
Participating clients are dependent on me, their prescribing doctor, to receive their 
weekly methadone prescription and as such, there is an obvious unequal 
relationship between us, which warrants further explanation. To address this 
understandable bias, prior to conducting the research, I had spent 2 years 
consciously building a rapport with these clients, ensuring I gained their trust. 
Clients were fully aware of the ethical motivations underpinning this research, 
which ultimately aimed to better address their needs by improving the delivery of 
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their MMTP. In doing so, I ensured, to the best of my ability, that client 
participation was both optional and truthful.  
The potential risks were minimal. However, as cited above, it had to be 
acknowledged that there was a risk of emotional distress for each participant 
during the interview given that they were discussing the personal challenges that 
are inherent in being a long-term client of a MMTP.  To minimise this risk I 
worked with the multi-disciplinary team, MDT, to ensure any upset that occurred 
both immediately and in the longer-term was appropriately managed by offering 
both immediate and regular follow-up counselling services.  Reassurance of 
confidentiality were given and participants were assured that they could cease the 
interviews at any point if they so wished.   
No incentives were given to participate in the study. Prior to the interviews, 
clients were urged to chat openly and honesty but were also advised that they 
were under no obligation to reply to all questions asked. During the interviews, 
new themes or foci of interest were signposted with clients in advance, removing 
any element of surprise and ensuring clients were happy to discuss the new area 
under review. Of uppermost importance, an outlook of needing to learn from the 
clients was portrayed and sustained throughout the interview process, which 
bolstered clients’ self-esteem and worthiness. It was reiterated that, through their 
participation in the study, they would be the key contributors to affecting positive 
change in the administrative policies and procedures of the MMTP. Empathy 
permeated the interviews and flashes of both melancholy and comedy were 
responded to appropriately.  
Following the University of Limerick Records Management and Retention Policy, 
E-transcripts were stored on a password -protected computer and hard copies were 
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locked in a cabinet in the main author’s office. University Hospital Limerick’s 
Research Ethics Committee granted full ethical approval for this study: REC 
Reference 131/16.  
Study 2, ‘Review of Ireland’s Take Home Naloxone Programme’ was a 
quantitative study on secondary data extracted from Ireland’s National Naloxone 
Database. This study received full ethical approval from University Hospital 










Chapter 4 Results Study 1  
4.1 Chapter Overview  
This chapter focuses on the results of Study 1, ‘Barriers to progressing through a 
Methadone Maintenance Treatment Programme: Perspectives of the clients in 
Ireland’s ‘Health Service Executive Mid-West Limerick Drug and Alcohol 
Services’. Results are structured chronologically. Initially, as seen in Diagram 1, 
emergent themes in the chronological development of an OUD as depicted by the 
participating clients of the HSE Mid-West MMTP in Limerick City. Firstly, 
results pertaining to the theme of childhood adversity are documented. Thereafter, 
as the clients moved from frivolous, recreational use through to full dependency 
the common chronological factors sustaining and nurturing their three-step 
journey unfold. Once their OUD was established, subsequent data analysis, as 
seen in Diagram 2, identified common life experiences, which influenced their 
illness. The majority of these influences were negative but some positive factors 
emerged and are documented accordingly. Finally, as seen in Diagram 3, 
participating clients of the MMTP voiced their own suggestions for improving 





Diagram 1 Chronological development of OUD in participating clients 
 
 
4.2 Individuals’ personal journeys to and through the MMT 
Programme in the HSE Mid-West Limerick Drug Services  
The following section expands on the main themes which emerged from the study 
in the development of an OUD as depicted by the participating clients of the HSE 
Mid-West MMTP in Limerick City. 
 
4.2.1 Adverse Childhood Experiences (ACEs) permeated their 
upbringings 
Childhood adversity was an exceptionally common occurrence across the 




•Adverse Childhood Experiences (ACEs)
Recreational 
Spoardic Use 
•Rates of initial recreational drug taking were exceptionally high, likely as a 





•Dual Diagnosis (Co-occurring disorders) with OUD and Mental Illness
•Concurrent illicit BZD Misuse/Abuse
Loss of Control 
•Hallmarked by boredom and loneliness and perpetuated by both 
destructive enviromental factors and negative therapeutic influences as 
outlined in section 2. 
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4.2.1.1 Personal ACEs 
In the category of ‘Personal ACEs’ all five adversities were documented.  
Reports of both emotional (1) and physical abuse (2) were common, with 
particular emphasis on paternal physical abuse.  
“I’d a traumatic experience in national school, I got bullied badly. I was 
suicidal even at about 11 or 12. And my father would have been a teacher 
then, and he never, he didn’t stick up for me…..”  Interviewee 6 
 “I suffer from problems over my father and my father is very physical to 
me here he broke my collar bone he broke my ribs, he broke my finger, he 
broke a lot of my bones you know what I mean my father when I was a 
child.  Like and he played me all of my life growing up you know what I 
mean” Interviewee 2 
Sexual abuse (3) was also reported.   
“When I was young like I used to be walking up and down it’s called the 
‘Boirin Lane’ and there used to be a man with a black fluffy dog the whole 
time. I would always see him like, but he was just a bad man. Then he did 
bad things to me” Interviewee 17  
 
Emotional (4) and physical neglect (5) permeated the transcripts.  
“I’d an unhappy childhood. It was very difficult. My parents didn’t get 
on” Interviewee 8 
“In 1975, I was only 11. I was in a, a what do you call it, you know them 
Christian Brother schools, locked away, eight years for taking nine apples, 
I got locked away in a school for nine apples. Life there was ‘Horrible, 
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horrible, horrible, horrible, some terrible things, Oh I don’t even want to 
talk about them...” Interviewee 9  
4.2.1.2 ACEs relating to household dysfunction  
All five ACEs pertaining to household dysfunction involving other family 
members were also documented.  
Mother being treated violently (6) was evident.  
‘‘I’d a father an alcoholic growing up. He was very abuse to all of us like, 
we all got it, my mother and all, you know. Interviewee 3 
Most interviewees reported exposure to a culture of illicit alcohol and drug misuse 
from a very young age, accounting for the ACE, ‘substance abuse in family’. (7) 
“I hate drink do you see because my brother and father years ago they 
used to drink and they used to kill each other so to drink I don’t like drink 
no I hate drink” Interviewee 11 
“I first saw drugs at home, my father was smoking hash...then he moved to 
cocaine” Interviewee 16 
“I ended up losing my mother when I was eight years of age; a drug went 
bad for her after she taking it…you know… Interviewee 17 
Mental illness (8) permeated these households adding to the adversities 
experienced in childhood.  
“My dad was very deep for reasons I know now like, but I didn’t know 
then. He was sick in the head” Interviewee 07 
“My brother is a schizophrenic” Interviewee 11 
  “My brother hung himself” Interviewee 17 
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 “I was in care for a bit & stuff. My mam died and my father couldn’t 
handle me” Interviewee 14 
Familial members in incarceration (9) was common.  
“My brother died after coming out, he done 9 years in prison and got out 
and died” Interviewee 11 
Finally, loss of parent (10) though death or abandonment was documented.  
“My father died when I was young enough…about 14 I’d say’. Alcohol 
killed him” Interviewee 5  
“My mother left me when I was 7. My dad has another family” 
Interviewee 10 
“My dad started like going out and he was meeting other women and stuff 
like that.  And he was always kind of like you know ‘’shush don’t tell your 
mother’’ kind of stuff like you know what I mean so” Interviewee 1 
4.2.2 Continuous exposure to adversities into adulthood 
perpetuated their ‘Recreational Sporadic Use’ of drugs 
Misfortune and difficulties continue to infiltrate their lives from childhood 
onwards. Often, their inability to cope with these relentless stressors resulted in 
commencement of heroin abuse and indeed frequently perpetuated its continued 
use thereafter.  The brief excerpts below summarises the struggles many 
individuals with OUD face on a daily basis. 
“My sister got murdered, she got shot dead. The hit was meant for me. I 
was the last one with my sister when she got shot so I always get the blame 
for her dying… My other brother got stabbed to death…. My other 
brother, he done 9 years in prison and he got out and died in the shower of 
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a heart attack…. My little brother just died, meningitis in the brain got 
him. My other brother he is a schizophrenic he is and his friends should 
know not to give it [heroin] to him do you get me.  My brother is the kind 
of one that will sit down and he will just talk to himself for the day do you 
know? If you give him a holy picture, he will talk to it for the day as well. 
It’s his friends that are doing it to him dragging him along now and 
making him rob this and rob that.  He is a pure misfortune do you get me. 
He’s in and out of prison. He lives in a mental hospital now. My mam fell 
to the ground there oh about twelve weeks ago. She is still in hospital 
since with two strokes in each side of the brain. She is supposed to be 
getting fed through a tube now.” The most stable influence in my life was 
the presence of my father. Unfortunately, he passed away in 2016, when 
“I was in incarceration” Interviewee 11 
4.2.3 Intensified Sustained Escalated Drug use  
This was fuelled by both mental illness and benzodiazepine misuse.  
4.2.3.1 Mental Illness, inclusive of Psychoses, Depression and Anxiety  
More frequently than not, reports of personal mental illness were recorded in 
tandem with these individuals’ heroin dependence. Psychoses, depression and 
anxiety disorders were the most common mental illnesses documented. These 
illnesses may have been present from a young age.  
“I suffered from psychosis since the age of fifteen. Schizophrenia 
psychosis I have” Interviewee 2 




“I lost two children in 9 days and I nearly lost one yesterday’. My son, he 
hung himself in prison, three days left in his sentence. His brother went 
out to the yard, they were in prison together. His brother was in the same 
cell as him but when he was out playing handball, the other was writing 
his suicide letter. My daughter committed suicide 9 days later. She went 
out, bought Xanax (alprazolam), and took the whole lot and just, she took 
about nine bags of heroin as well and just threw herself off the bridge. 
Afterwards, I tried to kill myself. But you can’t kill a bad thing…... He 
continues to suffer with depression and indeed was very low on the day of 
the interview itself, I’m on the verge of a breakdown and I know it myself, 
do you know, I feel like crying, I’m tormented, you know” Interviewee 12 
Individuals often expertly captured their misdiagnosis by health care professionals 
due to suffering from both an OUD and a mental illness. They often felt that their 
psychiatric team solely focused on their drug dependence and not their concurrent 
mental illness.  
“Yeah, I had depression there when I was out on bail for killing, for that 
incident, that really got me down, you know and I was the acute 
psychiatric unit for about two months, three months. They [the psychiatric 
team] were, they were mixing the two for me, they were trying to say that 
it was all got to do with the drugs and everything in my own heart and soul 





4.2.3.2 Illicit BZD Usage 
Not altogether surprisingly, an overwhelming proportion of interviewees were 
dually dependent on benzodiazepines (BZD). More often than not, individuals 
were buying these on the city’s black market. Due to the high demand for BZD 
outstripping local supply, the market was becoming more dependent on foreign 
suppliers, and purchasing them on the internet was commonplace. Individuals 
have no idea what they are purchasing, as these tablets are illegally manufactured 
and so do not resemble prescribed BZD in shape or size and indeed are often 
laced with other drugs.  
“At the moment, Benzos are a big thing in Limerick. They’re Spanish 
supposed to be, now there’s two different types, there’s ones that say U94 
on them. You can bust them in four, they’re supposed to be two milligrams 
and the shape of them is very funny, I’d say it would be very hard to copy 
them though. And then there’s other ones that says Xanax on the front of 
them, but they’re real thick and chunky and they have two on the back, 
they’re supposed to be two milligrams as well, but I took them and they 
made my urine dirty here’’ [A ‘dirty’ urine refers to a urine-testing 
positive for opioids] Interviewee 7 
Often, their supply of BZD was from the same supplier as their heroin and as 
such, BZD usage perpetuating heroin usage was evident. The cost of feeding their 
dual dependence also surfaced as a stressor in their lives. The use of BZD to 
enhance the effect of heroin was also apparent. Chaotic, alarming use of BZD was 
evident, where the risk of accidental OD was undisputed. 
“I mean if you are on benzos, you are half- asleep anyway so if you 
take heroin it’s going to push you over the edge like you know. You 
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can only go so far with benzos and once you reach that point if you 
took ten more benzos you still only get that far but if you took a bale 
of heroin you go that bit farther so I put them into the pot and inject 
then with the heroin with everything like so I inject them both 
together” Interviewee 12 
“I am only after taking 6-7 sticks [Sticks are a potent form of street 
Xanax, approximate equivalent to 2 mg Xanax] now [before 
interview]. I could take 20-30 of them a day. I buy sticks over Xanax 
because they are stronger. They are sent back from Spain or 
somewhere, they are charging a fortune for them anyway. Two euro 
fifty for one stick. But I take Upjohn 90s [1mg Xanax] now as well, 
maybe 10-15 a day” Interviewee 15 
4.2.4 Lack of Life Purpose, Boredom and Loneliness  
This picture formed the backdrop to their final descent to ‘Loss of Control’ on 
their opioid dependence. Individuals expressed a significant lack of purpose in 
their lives. Boredom was a dominant reference and was described as a reason for 
their continued heroin use. 
“Boredom is a big part I think, just sitting down at home with nothing to 
do thinking ‘’I will smoke that now it might knock me out’’ Interviewee 16 
Loneliness was a prevailing emotion linked to this subtheme. Lack of 
employment, a known contributor to the economic burden of this disease, had a 
significant negative impact on individuals’ self-worth. Many blamed having a 
criminal record for their unemployment. Inability to work due to disabilities 




“It’s very hard, motivation is lacking big time, yeah. I’m on disability at 
the moment, it’s because I’ve had DVTs in both legs over injecting [into 
the groin]. I don’t think I am fit enough to work… and with a criminal 
record” Interviewee 3 
4.3 Negative and Positive life experiences, which influence 
clients’ journeys 
Subsequent data analysis identified common life experiences, which influenced 
their journey. The majority of these factors negatively influenced their life paths 
by sustaining and at times escalating their opioid dependence. However, recurrent 
positive themes also emerged from the data, which warrant focus and further 
exploration.   





Ease of Access to Heroin
Peer Influence
Erroneous understanding of their illness
Poor Communication with allied health professionals
Stigma
Positive Factors
Structured Living Environment 
Familial  Incentive




4.3.1 Negative Factors 
Six negative factors emerged from the data analysis as described below.   
4.3.1.1 Turbulent Living Environment  
On analysing the data, three specific unstable living conditions emerged which 
perpetuated the continued use of heroin, living with an individual who also had an 
OUD, living in hostel accommodation and finally being homeless. Living with an 
individual who also suffered an OUD resulted in individuals stating they often 
sought heroin on behalf of their partners as opposed to fuelling their own habit.  
“If I had him sorted out there (referring to her current partner) I would be 
flying it’… If she did not source heroin on his behalf she felt he “would go 
out like do you know what I mean he would probably end up robbing 
something do you know I mean. It’s safer if I do it, do you know what I 
mean. I’m protecting, protecting him by getting it (money to fuel their 
habit) off my sister” Interviewee 1 
The environment most associated with continued use or frequent relapse was for 
individuals living in hostel accommodation.  
‘‘I’m in a hostel now and there’s two people dealing fucking heroin. It’s 
full of addicts. I can’t open my eyes, I can’t go outside my room without 
bumping in to someone and they’re either talking about drugs or doing 
drugs or a way of getting them, you know. It’s not an excuse but it’s just a 
matter of fact like, the heroin is just, it’s just rampant in that hostel and it 
was just a matter of time before my brain... gives in. It’s just everyone 
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who’s on heroin goes there to, to live, to use there because they know it’s 
an easy option’’ Interviewee 3 
Finally, homelessness was also reported as an environment that fuelled their need 
to use continuously. Motivation was hugely lacking in the homeless cohort, as 
being homeless secludes you from many basic needs.  
''If you haven’t got your own address you can’t get any help, medically, 
doctors, on assistance on anything. No, you can’t even get the dole. That is 
one of the main reasons I continue to use’’ Interviewee 2 
4.3.1.2 Ease of Access to Heroin 
Data analysis highlighted that the heroin supply in Limerick was plentiful, easily 
accessible, cheap and spreading to other communities. Ease of access was also 
confirmed by confirming a reduction in the price of heroin and its spread to other 
communities. 
“Oh yes oh yes in town yes. When asked if the regularly reported drug 
seizures were negatively affecting its supply, she replied, No it’s all over 
the place. ‘The other night whatever way I looked there was two fells that 
sells heroin sitting up on the next block of steps from my place’…. You 
would hear who has it do you know what I mean. They (the dealers) are 
waiting by pubs watching people coming out of the hostels and calling 
them asking telling them that they have gear…. You know now you can get 
three or four bags for fifty euro. About two year ago, it was twenty-five 
euro for a bag…. It’s getting bigger in the travelling community” 




4.3.1.3 Peer Influence 
Data analysis confirmed that all individuals cited the term ‘friend’, ‘mate’ or 
‘cellmate’ as the method by which all were first introduced to heroin. Though all 
17 lives differed greatly on their individual journeys, peer influence on initiation 
of their dependence, was the one constant variable.Thereafter, continued 
friendships with other drug takers perpetuated their dependence.  
A varying degree of insight with regard to these ‘friendships’ was noted. 
Nevertheless, even if they had this initial insight continued friendships with other 
drug takers perpetuate their continued use.  
“He wasn’t no he was a friend of mine but he was a snaky friend yes” 
Interviewee 15 
“I don’t really have any friends who don’t take drugs. There is one or two 
but they have kind of stepped back away from me because they don’t like 
being around me when I am taking drugs” Interviewee 16 
One potential solution, cited to address this issue, was to attempt complete 
isolation from their social scene. The only other escape from peer pressure was 
death.  
“I’ve isolated myself from all other addicts like, do you know, I don’t talk 
to any of them, I don’t, I’ve blocked all the drug dealers’ numbers” 
Interviewee 6 
“A lot of my friends are dead, a good thirty of my friends are dead either 




4.3.1.4 Erroneous understanding of their illness and methadone as a 
treatment option 
Uniformly, individuals had a poor understanding of the chronicity of their illness, 
the likelihood for long-term MMT or indeed of the rationale for using methadone 
as a medical intervention in their disease management. On initiation of treatment 
the average period, an individual felt they would need to be prescribed methadone 
was approximately 3-6 months.  
“When I first joined I thought I would be on it three to six months and then 
I would be going yes grand I am fixed now. But no.” Interviewee 12 
The average time in MMT across the 17 individuals was 7.5years. However, when 
asked re the likelihood for them needing ‘long-term’ methadone maintenance 
therapy, the vast majority of individuals were resolutely confident that they would 
not require long-term methadone therapy.  Over the last 12 years, interviewee 4, 
had repetitively engaged and re-engaged with the programme, relapsing regularly 
during the time but when probed as to why he believed he would not need ‘long-
term’ therapy answered confidently, “I think I’m passed that, you know, I think I 
am” 
Individuals’ confidence in remaining opioid free was disproportionate to their 
actual achievement. At the time of interview, interviewee 11, had succeeded in not 
using heroin for just one week but was adamant she would remain opioid free 
forever more. Not only so, but as a result of her week’s sobriety she now wished 
to cease methadone completely.  When probed if she knew of anyone that had 
successfully ceased methadone and remained opioid free thereafter she denied 




‘’Well I am clean now a full week.  It’s my first time I am clean and I am 
staying clean…. I don’t want it (the methadone) I am sick of it, it’s not for 
me… To be honest with you. I can’t think of anyone there that came off 
Methadone and stayed clean’’ Interviewee 11 
When asked re their level of education with regard to methadone itself individuals 
were uniformly poorly educated. Education levels of individuals’ families were 
also poor, which in turn resulted in lack of familial support for the treatment.  
‘’I got given a leaflet, so I just read through that, you know.’ (I learned) a 
little bit off YouTube’’ Interviewee 8 
‘‘No, no one explained to me how methadone works’’ Interviewee 9  
‘’My mam, she hates the stuff, she hates it because she thinks it’s the 
Devil’s drink’’ Interviewee 7 
4.3.1.5 Poor Communication with allied health professionals 
The majority of individuals reported a fragmented, poor and sometimes fractious 
relationship with their General Practitioners. They reported the fear of being 
stigmatised as the reason for hiding their heroin dependence and engagement with 
the MMTP from their GP.  
‘‘I didn’t tell my GP I had a heroin problem because I, I wasn’t telling 
anybody that I had a heroin problem. I was so anxious and nervous that I 
was going to get judged’’ Interviewee 8  
However, on finding out the individual was on the MMTP their relationship 
immediately disintegrated. The GP understandably felt there was no trust between 
them as reported by the individual recalling the encounter. The GP stated, 
‘’there’s obviously no trust between you and me.’’ The GP recalled all the times 
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she prescribed opioid based medications for the individual because of his reported 
pains and began to doubt the need or truth in his having needed them. As a result, 
she felt she could no longer remain his GP.  ‘’I just can’t deal with you.’’ As a 
result, the individual reported feeling abandoned by the health care system.  
‘‘I felt like a complete, excuse me, piece of shit. When I walked outside 
that door I never felt so lonely and so scared in my life’....  I’ve no GP 
from then till now’’ Interviewee 8  
As a result, many individuals refuse to engage with their assigned GP.  
“I don’t bother with him, being honest about it; I just go in for my 
medication. I even went in the other day to get a 3-month script so I won’t 
have to see him” Interviewee 9  
Worse yet, some individuals reported having no access to primary care 
whatsoever.  
“No, I’ve no GP at the moment. ‘I don’t know how to do it (get a new GP), 
nobody is helping me with that” Interviewee 10  
Reports of a similarly disjointed relationship with community mental health 
services were documented. Poor communication between community day 
hospitals and detoxification centres was evident and the client suffered as a result.  
“I was seeing a psychiatrist. I was on lyrica for general anxiety…. But I 
haven’t gone to him in years. I got off the Lyrica when I went to treatment 
you see” Interviewee 6  
Unfortunately, the client’s anxiety remained untreated after in-house 
detoxification failed to manage his drug dependence.  
Individuals’ lack of understanding of their prescribed treatment also fueled the 
mounting miscommunication between them and their psychiatric team.  
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“See they (referring to psychiatric day hospital) give out a load of drugs, 
like they, they put me on an antidepressant I know, but I don’t know why 
they put me on it when I’m coming down off Benzos… because I think it 
(concurrent anti-depressant medication) makes it harder to come off it 
(BZDs) in the long term. They didn’t explain nothing, (they just said) we’ll 
put you on this and it’ll help you like and now he’s after doubling my dose 
yesterday, I was on ten now I’m on twenty… Do you know I hope I’m not 
going to have a problem down the line with them” Interviewee 7  
Furthermore, poor inter-communication between allied health professionals was 
also evident. Interviewee 12 reported suffering with panic attacks. His GP referred 
him to the local psychiatric hospital where benzodiazepines were prescribed as a 
treatment modality. However, he reports his GP not agreeing with this treatment 
plan. 
‘’When I came back to my GP he then took me off the benzos. I told him I 
still get panic attacks but he said, ‘’it’s all in your mind’’ and to just 
exercise your way out of it like’’ Interviewee 12 
4.3.1.6 Stigma 
Individuals reported feeling stigmatised due to their engagement with the MMTP 
by not only their family, friends and neighbours but by society as a whole. 
Embarrassment was a common recurring phrase. As a result, they try to hide their 
methadone usage from everyone, often inclusive of their own family members. 
They are ashamed of their dependence and the negative connotations associated 
with needing treatment for it, as reflected in the following five short excerpts from 
the transcripts.  
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‘’There is an awful stigma when people know what you are on. They will 
stop looking at you if you know what I mean’’ Interviewee 2 
‘’I find it embarrassing in my own town. I just pull up in my van around 
the corner from the pharmacy and just kind of sneak in’’ Interviewee 6 
‘’When I know someone that comes in to the pharmacy I just sit there like 
a zombie, embarrassed. It can be hard. People can look down their nose 
when you are on Methadone’’ Interviewee 10 
Interviewee 12 was embarrassed by the fact that the public was, ‘’paying taxes for 
keeping people on methadone’’. When challenged and asked if the public should 
not view opioid dependence as a chronic illness, much like diabetes, and requiring 
methadone was much like diabetics needing insulin he defended the public’s 
perception of heroin dependence 
‘’You are not born with the choice of diabetes but you are born with the 
choice of not taking heroin’’ Interviewee 12 
 
4.3.2 Positive Influences 
Three positive factors emerged from the data as described below. These findings 
are of paramount importance as it is these factors which promote abstinence and 
improve the overall quality of life for the individual with a chronic dependency on 
opioids.   
4.3.2.1 Structured Living Environment 
Often, the more regularised their living conditions were the greater their likelihood 
was of remaining opioid free. Three specific environments were tabulated, prison, 
hospital and when housed in a drug free environment. Interviewee 13 reported 
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finding the structure and governance that prison offered, ‘’behind a steel door’’, a 
welcomed reprieve from their chaotic lives fueling their drug habit.  
Reports of purposefully getting caught committing crimes to ensure imprisonment 
were documented, as individuals knew the strict regime of prison had the potential 
to help them succeed in their quest for sobriety.  
‘’I spent a lot of years in jail. It was down to drugs, theft to supply 
my habit. I was using gaol as a rehab, do you know, I was going out, 
committing crimes and getting caught on purpose just to go in to 
gaol to get off the gear. I couldn’t get off it you know on my own 
outside. Gaol saved me enough of times. I got clean in prison, yeah. 
I got a job as a cleaner and, do you know, kept my head down. It 
worked for me. It gave me structure that you don’t have on the 
outside’’ Interviewee 4 
Interviewee 11 felt prison has saved her life. She was also so desperate to escape 
the clutches of her addiction that she voluntarily presented herself for incarceration.  
''Oh, it done me the world of good I know. If I didn’t go to prison, I 
would have been found dead to be honest with you. I handed myself 
into the prison….Yes I had to, or else I would have fell to the ground 
and just died because I wasn’t eating, all I was doing was smoking 
smoking, smoking’’ Interviewee 11  
In addition, when given the opportunity to move from hostel accommodation, as 
documented above, to a drug-free apartment successful cessation was noted.  
‘‘I was in the hostel. Everyone was on heroin; nearly the whole 
building I’d say was on it. But, they got me and my partner an 
apartment, it’s beautiful. And ever since we got in to that apartment, 
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we had no one around us that was on heroin, so I think that’s what 
kind of helped us’’ Interviewee 5 
Other ‘controlled’ environments where successful reprieve from their addiction 
occurred was when hospitalised for prolonged periods or indeed when housed in a 
specific drug-detoxification centre. Unfortunately, on termination of their 
‘confinement’ in prison, hospital or a detoxification centre all individuals relapsed 
once they re-entered their own community setting. Even, those that were re-
housed eventually re-engage with old ‘friends’ and habits and relapses were 
unanimously documented.  
4.3.2.2 Familial Incentive 
At various points in their journeys, these individuals had periods of sobriety 
driven by certain incentives, mainly family members, particularly children or 
younger siblings. Their dependence result in their journeys being chaotic and 
quite often unmanageable but their overall ultimate wish in life is for simplicity. 
Their aspirations are basic, a normal familial home with full access to their 
children, where the can function as a stable parent and ultimately gain the respect 
of their children, siblings and other family members.  
‘’My ultimate goal is to, just to have my family back around me and get 
the house back to normal’’ Interviewee 4 
Interviewee 12, was motivated by his daughter’s acknowledgement that her 
classmates were referring to him derogatively as a ‘’junkie’’.  
‘’That was kind of like one of the nails in the coffin for me, it was like 
going, Jesus Christ I had better get off this stuff…. But it’s an uphill 
struggle’’ Interviewee 12  
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Interviewee 11 did manage to remain opioid free when in prison and is aware of 
the benefits of a structured routine, as a result feels a detoxification centre may be 
her best option to rid herself of her addiction. 
‘‘I would go into treatment at some point. To get my kids back, to live 
normally, just being a normal mother for my kids, that’s all I want’’ 
Interviewee 11 
 
4.3.2.3 Belief in the medicinal properties of Methadone 
An extremely favourable relationship with regard to the pharmacological properties 
of methadone was reported, particularly in the early phases of treatment. The reports 
ranged from the very basic to the more complex.  Individuals were exceptionally 
grateful for methadone’s ability to prevent the symptoms of withdrawal, often 
giving a very honest description of the positive effects with regard to this. Beyond 
this basic function, other individuals viewed methadone as a step closer to a more 
‘normal life’ as it releases them from the grip of their disease and allows them to 
choose their path in life. Others viewed it as giving ‘a glimpse of some kind of 
future’’. Some viewed methadone as quite simply, “lifesaving”. 
 ‘‘I’m not waking up sick, I don’t have to think about who I am going 
to rob or where I am I getting the money you know’’ interviewee 14 
‘‘It just gives you time, it gives you a choice, methadone actually 
gives you the choice to take or leave heroin’’ Interviewee 3  
‘’I went on Methadone because if I didn’t go on it I would’ve ended 




4.4 Clients’ personal proposals for improving their journey 
Final data analysis identified individuals’ personal suggestions for enriching their 
journey. At the end of each interview, each individual was given the opportunity 
to suggest changes they would implement to the programme to optimise the 
effectiveness of the MMMT Programme. The most common derived suggestion 
was contentious as it involved limiting individual time on the programme, which 
belies the harm reduction philosophy in treatment.   
Diagram 3 Clients' personal proposals for improving their journey 
 
4.4.1 Enforce Time Limits on phases of their journey within the 
MMT Programme 
Interviewees suggested a very strict induction phase of treatment with a well 
thought out plan to enforce it. All new individuals would be limited on the 
programme to a 5-week treatment plan, increasing their dose incrementally by 5mls 
to a maximum of 50mls.  
‘‘If you don’t bring back a clean sample after this, that is it for you, 
we will talk to you next month. We have someone else in line who 
Enforce Time 
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needs to try this. Try it that way and see if it works or if it doesn’t’’ 
interviewee 2 
Other individuals not only supported the above measures but also took it one-step 
further by suggesting additionally increasing the weekly urine testing to twice 
weekly, admitting that individuals can orchestrate their opioid use during a once-
weekly sampling regimen, to give false negative samples.  When questioned as to 
the effect such sanctions would have on their own engagement with the programme 
some felt they would respond positively and that it might be the ‘wake-up call’ they 
needed.  
‘’Because I could leave here now today and use Friday, Saturday, 
Sunday and Monday and then come back on next Friday and give a 
clean urine’’ ….  People are abusing the system’’ Interviewee 12 
However, other individuals felt such sanctions would be inappropriate for their 
particular journey, citing long-term engagement in the programme as a justifiable 
reason not to adhere to it. Others could not rationalize why they were above 
sanctioning. Implying a harm reduction philosophy should be in place for them but 
not others.  
‘’But when you get to fifteen to twenty years like I am using 
methadone you have an understanding of it…. You need it’’ 
Interviewee 14  
 ‘‘Throw them all out I would’… ‘I would, but then when it comes to 
yourself and a doctor is telling you, ‘’Oh I am going to throw you 
off the methadone’’ it’s a different story, do you know what I 
mean?’’ Interviewee 1  
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4.4.2 Employ a Multi-Sectorial Approach 
Individuals strongly advocated for the integration of their methadone treatment with 
other relevant services, such as psychiatric services, GP and medical care and 
housing services. One of the most notable benefit to an integrated approach is that 
individuals would access these services more conveniently, thereby improving 
utilization of these resources.  
‘’I just think ye yourselves doctors, and psychiatrists, and housing 
(representatives) if you could roll all that into this clinic it would be 
fucking dynamite. Can you image the amount of people in Ireland 
you would be helping? The organisation you create would be 
phenomenal it would be phenomenal supported by government and 
things like that because it would have to be supported by the 
government’’ Interviewee 2  
‘’If we had people here to help with the house and maybe help with 
getting me a GP that’d be brilliant’’ Interviewee 10  
 
4.4.3 Provide Education 
This subtheme imbued many of the transcripts. References were made to 
educating the public and a specific suggestion was to revise our wording of 
methadone as a ‘substitute’ as this terminology had exceptionally negative 
connotations and participants believed as a result, fueled the publics’ 
misunderstanding of the treatment.  
‘‘Educate people, because when people hear you’re on methadone they 
just assume you’re on heroin and they don’t see it as a treatment, they see 
it as a substitute’’ Interviewee 8  
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Participants also felt their immediate family and friends ‘‘My mother still thinks 
it’s, you know... a substitute’’ Interviewee 3, as well as society’s youth needed to 
be properly educated re methadone.  
‘’Oh Jesus the kids definitely need to be educated. A lot of these kids 
wound up taking drugs they didn’t know’ (what they were taking). Me, I 
hadn’t a fxxking clue. I thought if you smoke this stuff I thought grand you 
could drop it and that would be it.  Little did I know four days later I 
walked out of that man’s house that I would wind up an addict’’ 
Interviewee 12 
4.5 Chapter Conclusion  
Findings in this chapter are of upmost importance. It answers two exceptionally 
important questions. Firstly, section 4.3.2 highlights which factors improve the 
quality of life in a person with a chronic opioid dependency who has already 
suffered adverse childhood experiences and toxic stress. Of equal importance, in 
section 4.4 their suggested amendments to the current MMTPs in Ireland are key 
factors to be addressed if ever we are going to optimise the management of their 
OUD.  
In conclusion, an enriching insight into the personal experience of each individual 
client’s journey to and through the Mid-West of Ireland’s Programme for 
Methadone Maintenance Treatment (MMT) emerged from the data analysis. Their 
journeys, though each unique, had common chronological sub-themes. 
Subsequent data analysis identified common life experiences, which influenced 
their journey both negatively and positively. Final data analysis identified clients’ 




Chapter 5 Results Study 2 
5.1 Chapter Overview  
This chapter documents the results of Study 2, ‘An in-depth review of Ireland’s 
Take Home Naloxone Programme’.  
The results of Study 2 can be subdivided into descriptive analysis and statistical 
analysis. The descriptive analysis first looks at the characteristics pertaining to the 
OD patient themselves and subsequently the characteristics of the OD scene are 
shown. Thereafter, using a logistical regression model, statistical results on the 
variables that influence a patient’s hospital attendance, are presented. Results of 
the accuracy of the LR model in predicting the likelihood of hospital attendance 
shows an accuracy of 77%, which is highly reassuring in interpreting these results. 
As results indicated that the variable, which most significantly influenced hospital 
attendance, was, ‘if the patient received 3 or more doses of naloxone’, (P value of 
0.01), subsequent testing using Welch t-tests were undertaken to analyse which 
variables, if any, influenced the number of doses administered. Results showed 
the only significant variable was age.  
5.2 Descriptive Analysis  
The descriptive analysis for this study can be subdivided into characteristics of the 
OD victim and characteristics pertaining to the OD setting itself.  
5.2.1 Characteristics of Overdose Patients 
There were no deaths recorded. As tabulated in Table 7, slightly more women 
than men received naloxone. Just over half of the dataset were aged between 30 
and 40, with the average age being just over 33. The majority of ODs involved 
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people registered on an MMTP, with about the same number of people also 
having injected drugs at time of OD.  
Table 7: Characteristics of Overdose Patients 
Characteristics of Overdose Patients Frequency Percentage 
Sex Male 44 44% 
Female 56 56% 
 
Age < 30 years 24 24% 
30 – 40 years 55 55% 
> 40 years 15 15% 
Unknown 6 6% 
 
Registration on MMTP Yes 62 62% 
No 23 23% 
Unknown 15 15% 
 
Had injected drugs at 
time of OD 
Yes 60 60% 
No 3 3% 
Unknown 37 37% 
 
5.2.2 Characteristics of Overdose Scene  
As tabulated in Table 8, breakdown of naloxone use by CHO area in Ireland 
showed the majority of uses were in Dublin (CHO areas 7 & most predominantly, 
CHO area 9) with the south-west region (CHO 3), containing Limerick City, the 
next largest. Rarely a person was alone when they overdosed, with 1 or 2 people 
being the most common grouping. Hostel workers were in charge of the OD scene 
approximately 80% of the time, with peers overseeing the remaining 20% of OD 
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scenarios. The hostel worker/peer factor was broken down further, looking at their 
individual response to an OD i.e. did they call an ambulance and did they 
administer Basic Life Support (BLS), as shown above. When called, the majority 
of ambulances arrived in 10 minutes or less. We can see that the distribution of 
doses administered is almost uniform for 1 or 2 administrations, with 3 or more 
doses having slightly less recorded instances. In the overwhelming majority of 
reported ODs, the Gardai were not present. Most notably, in over 40% of cases 




Table 8: Characteristics of Overdose Scene   
Characteristics of Overdose Scene Frequency Percentage 
CHO area 1 0 0% 
2 3 3% 
3 11 11% 
4 1 1% 
5 9 9% 
6 4 4% 
7 16 16% 
8 0 0% 
9 54 54% 
Unrecorded 2 2% 
Number of others present None 11 11% 
1 37 37% 
2 30 30% 
3 or more 22 22% 









Ambulance called Yes (n=91) Peer 8/17 47% 
Worker 83/83 100% 
No (n=91) Peer 9/17 53% 
Worker 0/83 0% 
Length of time for 
ambulance arrival  
(for the 91 occasions for 
which it was called)  
< 10 min 60/91 66% 
> 10 min 28/91 31% 
Unknown  3/91 3% 
Specifics of the Basic Life 




Peer 4/17 23% 





Peer 10/17 59% 
Worker 18/83 22% 
Not given BLS Peer 3/17 18% 
Worker 12/83 14% 
Number of doses of naloxone 
administered in total  
1 34 34% 
2 38 38% 
3 or more 26 26% 
Unrecorded 2 2% 
Who administered naloxone Peer 17 17% 
Worker 83 83% 
Were the Gardai present? Yes 4 4% 
No 96 96% 
Did patient go to the hospital 
with the ambulance 
(for the 91 occasions for 
which it was called) 
Yes 53 58% 
No 38 42% 
 
5.3 Statistical Results 
Due to the small sample size in this study, results were deemed valid if they were 
significant at the 10% level i.e. had p-values < 0.1. This does increase the chance 
of making a type 1 error. The probability of this happening is the p-value of your 
test. Increasing the cut-off from 5% to 10% is not without its drawbacks, however 





5.3.1 Logistical Regression (LR) Results 
To assess the predictive ability of the LR model, the data was split, with 75% used 
to train the logistic regression model. The model was tested on the remaining 25% 
of the data. 17 were predicted correctly (the diagonal entries 9 & 8) and 5 (the off-
diagonal entries 4 & 1) were incorrectly predicted, resulting in a classification 
accuracy of 77.27% (17/22), as summarised in Table 9.  
Table 9: Classification Table 
Yes/No Predicted No Predicted Yes 
No 9 1 
Yes 4 8 
 
The ROC curve (Diagram 4 below) confirms the accuracy of the LR model. 
  




5.3.1.1 Interpretation of the LR Model Coefficients  
Table 10 summarises the LR model coefficients, showing which factors impact 
the likelihood of the OD patient attending hospital. For statistical significance at 
the 5% level, the 95% confidence interval should ideally not cross zero. However, 
due to the relatively small population, data quality and data confidence issues we 
included variables that were more marginal.  As is evident from the analysis the 
number of doses received is statistically significant if the patient receives 3 or 
more doses (P value of 0.01) and indeed receiving 2 doses has borderline 
significance with a P value of 0.12. Likewise being male has a negative borderline 
significance with a P value of 0.08 and the next variable of most significance 
thereafter is being on a methadone maintenance treatment programme which has a 
P value 0.14.  
 
5.3.1.2 Interpretation of the Odds Ratios  
A male is approximately 4 times less likely (0.258 times) to go with the 
ambulance than a female according to the model, all other things being equal. 
Registration on a methadone maintenance methadone programme equates with 
being almost 3.9 times more likely to go to the hospital than not. The more doses 
a person receives, the more likely they are to go with the ambulance. A person 
who receives two doses is 4.3 times more likely to go to the hospital than a person 
who only receives one, all other things being equal. If they receive three or more 
doses, they are over 13 times more likely to go to the hospital than if they just 













P Value  




-1. 42377 1.167 -3.862  -  +0.838 0.2224 
Male Sex  -1.35459 0.78 -3.007 -  +0.101 0.0824 
Individual of MMTP* 
(Yes) 
1.34900 0.927 -0.391-  +3.317 0.1455 
Individual of MMTP 
(Unknown) 
0.52819 1.308 -1.992 -  +3.274 0.6863 
Injected opioid at time 
of OD (Yes) 
-1.14808 1.78 -5.081 -  +2.551 0.5190 
Injected opioid at time 
of OD (Unknown) 
-0.02478 1.848 -4.101 -  +3.754 0.9893 
Number of others 
present at OD 
0.04220 0.25 -0.484 -  +0.526 0.8662 
Not put in recovery & 
No CPR administered 
-0.814 1.184 -3.221 -  +1.505 0.4916 
Recovery position only 
applied (No CPR 
given) 
-0.944 0.963 -2.959 -  +0.911 0.3267 
Age 30-40 -0.456 0.813 -2.129 -  +1.111 0.5749 
Age 40+ 0.389 1.163 -1.878 -  +2.771 0.7380 
Two doses of naloxone 
administered  
1.459 0.936 -0.282 -  +3.453 0.1190 
Three + doses of 
naloxone administered   
2.589 1.059 +0.674 -  +4.912 0.0145 
Time for ambulance to 
arrive over 10mins  
-0.615 0.852 -2.305 -  +1.141 0.4697 
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5.4. Welch’s Test 
Subsequent analysis employing Welch’s t-test was done to ascertain if any of the 
following variables influenced the number of naloxone doses administered: 
gender, registration on a MMTP at the time of OD, injecting heroin at the time of 
OD and a victim’s age. As preliminary analysis of the data set showed an 
imbalance in sample size allocations, student's t-tests were unsuitable to undertake 
this analysis and as a result, Welch's t-tests were performed instead. These tests 
are often referenced as "unpaired" or "independent sample" t-tests, as they are 
typically applied when the statistical units underlying the two samples being 
compared are imbalanced, such as in this case.  
Gender was not found to have a significant effect (p-value 0.8). Likewise, whether 
a person was registered on a MMTP or not was not found to have an effect (p-
value 0.85). If the person had or had not injected heroin at time of administration 
was also found not to have an effect (p-value 0.73). 
5.4.1 Result of testing ‘Age’ in Welch’s Test  
The only factor, which did influence the number of doses administered, was the 
person's age. A person with an above average age received more doses (2.49) than 
those with a below average age (1.91) (p-value = 0.065), where average age was 








Chapter 6 Discussion  
6.1 Chapter Overview  
Three consecutive, independent phases in developing an OUD underpin the 
framework of this thesis: Initial sporadic, drug experimentation transitioning for 
some to a more intense, sustained pattern of opioid abuse to a final descent for a 
select cohort to complete loss of power over opioid consumption. With sustained, 
escalated use and full immersion into opioid dependence, a lack of life purpose 
was evident in all transcripts from Study 1, where boredom and loneliness imbued 
the participants’ lives. This is in line with other researchers findings. (216, 217). 
All too often, as Study 2 highlights, the desperate outcome for many of these 
individuals’ journey through OUD is death from OD.   
The aim of Study 1 was to give clients of the ‘Drug and Alcohol Services in the 
HSE Mid-West Limerick MMTP’ a voice, to document their lived experience of 
opioid dependence before, during and after their ‘three-phase journey’ through 
OUD.  The goal was to improve the service in a two-prong approach. Firstly by 
establishing patterns of similarity in clients’ journeys, which would flag the 
clients’ and their children’s high-risk status on admission to the MMTP. This in 
turn would allow an early tailored care plan to be put in place to optimise their 
chance of successfully engaging with the MMTP and other relevant, available 
services to gain the most from what they had to offer. Secondly, hearing from the 
voice of the service users themselves on how to improve the service would allow 
potential changes to be made to improve their overall experience and engagement 
with the service. Unfortunately, ‘opioid-induced deaths’ are all too commonly the 
outcome of an OUD. To combat these fatalities, Ireland initially piloted, and then 
rolled-out a THNP nationally in 2015.  Study 2 aimed to gain an insight into the 
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programme in terms of number of reported uses of naloxone and the 
accompanying patient and setting characteristics since its inception in late 2015 
until March 2018. This study had two primary objectives, descriptive and 
statistical analyses of the selected secondary data. Post naloxone administration, 
statistical analysis aimed to predict the likelihood of a patient attending hospital.  
Many interesting, recurrent themes were disclosed to me the interviewer in Study 
1. This chapter will initially focus on the power dynamic in the relationship 
between the participants in this study and me as their prescribing doctor. It will 
then further exploring ACEs, with an explicit focus on their relationship with 
stress in later adulthood. Subsequently, the discussion will centre on dually 
diagnosed individuals, with a specific focus on benzodiazepine misuse. The final 
theme explored will be that of therapeutics, with a specific focus on the fallacies 
surrounding methadone as a therapeutic agent, the stigma inherently experienced 
by those registered on a MMTP and finally, clients’ own insights on methadone as 
a therapeutic modality is explored.  
The discussion will then move on to Study 2 of this thesis. In this study, initial 
analysis of the secondary data from Ireland’s THNP revealed the reporting 
mechanism in use to be quite onerous and as a result a potential barrier to the 
recruitment of data nationally. Descriptive data analysis in this study gave an 
overall picture of both patient and scene characteristics, which are important to 
note on Ireland’s THNP. This was the first analysis ever done on these variables. 
Finally, post naloxone administration in the community, statistical analysis aimed 
to create a LR Model from the data set, which could predict the likelihood of a 
patient attending hospital. The latter half of this chapter will discuss these three 
separate issues in detail, the reporting mechanism, the characteristics of the data 
set and the LR Model. 
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6.2 Power dynamic in the patient-doctor relationship 
It would be a failing of this thesis not to further explore the ethical challenges that 
my being both the researcher and the participants’ prescribing doctor had on the 
study. Undoubtedly, an unequal balance of power exists in this relationship. 
Qualitative health researchers agree that researchers must be mindful of this 
imbalance as often boundaries are blurred in the relationship. (218) Also the effect 
of the sensitive and emotive issues under discussion on the researcher must be 
acknowledged. (219, 220) The ethical dilemmas which arise due to the 
changeable, interpersonal nature of qualitative research must also be addressed. 
Building rapport and ‘camaraderie’- developing techniques can cause 
misconstructions (221) and result in ‘shifting boundaries’ within the therapeutic 
relationship (222) These techniques aim to create a relaxed, friendly and ‘non‐
hierarchical atmosphere’ favorable to the disclosing of personal information (223, 
224) but concurrently can distort the doctor patient relationship.  Supported by 
current research (225), reflexivity or continuous ‘critical reflection’ on these 
issues throughout the research process was essential. (226) Reflexivity, as 
documented by Phelan et al, can be ‘used as a tool to enact ethical practice’. 
(227) Supervisory meetings always ensured to allow time for critical reflection on 
sentiments, principles and attitudes in relation to the research. They re-centred and 
refocused my approach to ensure I was engaging appropriately with participants 
during each interview, as appropriate practices in qualitative research are ‘fluid’ 
and not prescriptive. (226) 
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6.3 Adverse Childhood Experiences  
The theoretical concept of ‘Adverse Childhood Experiences’ and their impact on 
acting as a catalyst for recreational sporadic drug use and subsequently 
perpetuating an opioid dependence was explored in the literature review chapter 
of this thesis. It was noted that Felitti, Anda and colleagues first described ACEs 
in 1998. (26) Over the intervening 20 years since Felitti at al’s seminal study, 
ACEs continue to be of increasing international concern and consequently there is 
a mounting wealth of research, which validates that chronic stressful experience in 
childhood, can lead individuals on a health-harming life course inclusive of illicit 
drug use. (30) More recently, research tells us that ACEs occur frequently - 67% 
of the population have experienced a minimum of one ACE. (228) However, high 
ACE scores (scores of four or more) are robustly linked with an increased risk to a 
person’s overall health status. (40) 
1n 2015, Public Health Wales surveyed 2,028 Welsh adults (25) using Felitti’s 
internationally indorsed questionnaire. (26) In total, 4.4% of respondents admitted 
to experimenting with crack cocaine or heroin. However, the frequency of heroin 
or crack cocaine use increased with each ACE count, increasing from less than 
2% in those with no ACEs to greater than 20% for those reporting four or more 
ACEs. This correlation remained constant after adjusting for age, gender, 
ethnicity and social class. The probability of respondents who had endured four or 
more ACEs partaking in heroin or crack cocaine use were greater than 15 times 
than those who had undergone none. After amending the data to match the 
demographic of the national population, findings indicated that if no persons were 
subjected to ACEs, then the incidence of participants who had ever experimented 
with heroin or crack cocaine could be lessened by 66%. A take-home stark 
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statistic of this Welsh study on ACEs showed that compared with no ACEs, those 
with exposure to 4 or more ACEs were found to be 16 times more likely to have 
used crack cocaine or heroin. 
Studies specific to illicit drug use show that the risk of early experimentation with 
substance abuse increases2-4 times for each ACE and nearly two thirds of 
injection drug use can be linked to ACEs. (229)  From a gender perspective, 
research indicates that ACEs are more prevalent in females than males and that 
there are noteworthy gender variances in the correlation between separate 
classifications of ACEs and ‘mental and substance use disorders’ (MSUDs). 
(230) For instance, physical abuse was associated with female mental health 
disorders but with male substance use disorders (231), which may also explain 
increased reports of female mental health = and greater rates of male substance 
use disorders. (232)  
A most recent study conducted in 2017, examined the association of ACEs with 
lifetime mental and substance use disorders among men and women aged over 50. 
Given the aging cohort of opioid use disorder, this study is particularly relevant. 
Increasing rates of substance misuse in mature adults is often credited to a more 
liberal culture of substance use amongst the ‘baby boomers’ who are now entering 
adulthood. (233) Set in the US, the study tested links between ten types of 
childhood adversities and MSUDS in the growing older-adult population. Results 
confirmed that just over half of participants stated suffering one or more ACE, 
and ‘parental/other adult’s substance abuse’ was the most frequently reported 
ACE, which supports the theory of the ‘cycle of violence’, as explored in the 
literature review of this thesis. From the perspective of acquiring a substance use 
disorder, results showed physical, sexual, psychological abuse and/or exposure to 
parental/other adult’s substance abuse significantly increased one’s risk. For men 
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only parental divorce was a significant factor for drug use disorder. The link 
between sexual abuse and drug use disorder also appears to be greater for males 
than females.   
From an Irish perspective, a recent survey undertaken by Dr. Sharon Lambert and 
Graham Gill-Emerson, surveyed the level of trauma among Cork Simon service 
users ‘Cork Simon Community: Moving Towards Trauma Informed Care. A 
Model of Research and Practice.’ (234) The Simon Communities in Ireland are 
comprised of eight self-regulating communities based in Cork, Dublin, Dundalk, 
Galway, the Midlands, the Mid West, the North West and the South East.  
Supported by a national office, they have served to tackle all forms of 
homelessness throughout Ireland for over 45 years.  
In this survey, from a drug dependency perspective, the second highest ACE 
experienced by this homeless cohort was ‘substance misuse by a family member’, 
experienced by over 70% - more than twice what the public in Felitti’s original 
ACE study reported. (26) From an age perspective, substance abuse in the family 
was reported by 100% of the youngest age category, 18-26 year olds, which was 
1.3 times higher among this age group compared to the next highest scoring age 
group. Those with ACE scores of 4 or more initially engages with alcohol and 
drugs at an earlier age and reported double the rate of drug od compared to those 
with ACE scores less than 4. (234) These findings highlight the importance of 
psychosocial interventions that aim to meet the health care needs of victims of 
childhood maltreatment which will ultimately reduce the number of people with 
drug dependency in Ireland.  
Trauma in early childhood impacts how we respond to stress throughout our lives 
and as stress plays an integral role in developing and sustaining an OUD (235), it 
126 
 
merits a brief look here.  Exposure to early stressors in life, such as, poor 
parenting, family dysfunction, and adverse neighbourhood characteristics 
establishes a lower “set point” for a child’s internal stress system. It has been 
found that early life trauma can alter the brain’s stress regulatory systems, which 
influences an individual’s ability to regulate emotion and respond to fear. (236) 
Consequently, individuals may be more vulnerable to health harming behaviours 
in later life. (237) If an individual has a heightened stress response, they are likely 
to attribute a high worth to substances that offer temporary relief such as opioid 
misuse. In contrast, activities, which typically offer satisfaction, such as, 
meaningful, familial relationships, are undervalued because in the Individual’s life 
they have never been fulfilling. (238) It is well established that as dopamine levels 
decrease, the craving for drug use increases. Stress reduces the function of 
dopaminergic receptors in the emotional circuits of the forebrain (239) and 
consequently increases the long term craving for opioids. The reward value in 
drug use is enhanced by stress and even after periods of abstinence, stress can 
provoke relapse. (240)  
 
6.3 Dual Diagnosis  
Unsurprisingly, adversities in childhood more often than not were the 
steppingstone for continued adversarial challenges into adulthood. As a result, 
mental illness and illicit use of non-prescribed benzodiazepines (BZDs) 
permeated the lives of the individuals in Study 1. Dual diagnosis is, as defined by 
the Royal College of Psychiatrists, 2002, ‘the co-existence of both mental health 
and substance misuse problems including both drugs and alcohol’. (241) Each 
disorder in itself is chronic and relapsing, travels an independent course and is 
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capable of influencing the other disorder. Dual diagnoses increase the risk of 
individuals who recreationally engage in opioid use developing an opioid use 
disorder (242). Similarly ,in comparison with the general public,  the frequency of 
psychiatric disorders, including other SUDs, increase in individuals with an 
established opioid use disorder.(243) The analysis of the transcripts from study 1 
showed a complex relationship between the two as diagnoses vary as listed below: 
1. A primary psychiatric disorder with secondary substance misuse 
2. A primary substance misuse disorder with secondary psychiatric illness 
3. An underlying traumatic experience resulting in both substance misuse 
and mood disorders 
Implications of a dual diagnosis are far reaching. Dual diagnoses present with 
substantial clinical challenges and negatively influence an individual’s ability to 
initiate and respond appropriately to treatment. They result in a greater use or 
misuse of services and increased morbidities and death rates. (244) For 
individuals with a dual diagnosis, optimizing treatment of their psychiatric 
disorders is essential to improving the outcome of their opioid use disorder.  
Furthermore, the earlier an individual initiates opioid use the more likely they are 
of developing a co-morbid psychiatric illness.  (245) Knowledge of this should 
inform our clinical practice in identifying individuals at an increased risk of dual-
diagnosis.  
Two main barriers in addressing the needs of dually diagnosed individuals lie in 
firstly diagnosing the problem and secondly collaborating with relevant 
stakeholders to ensure their treatment plan is optimal. A frenzied lifestyle is often 
synonymous with undiagnosed co-existing requirements. This negatively affects 
individuals’ ability to attend scheduled appointments and engage with mainstream 
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facilities. The resultant outcome being dually diagnosed patients are the most 
vulnerable and marginalised in society.   
In the current Irish health and social care system, services are poorly equipped and 
resourced to address concurrent illnesses. The system serves to meet the primary 
need of an individual, substance or mental health. Often treatment is provided 
from separate divisions within the HSE, not working collaboratively but in 
isolation. In addition, many support services are delivered by the NGO sector who 
may be working independently of statutory providers. The input of the Mental 
Health Service is clearly of paramount importance in meeting the needs of 
individuals with an OUD. In the Mid-West MMTP, counselling and out-reach 
support is available but the coordinated input of a mental health multidisciplinary 
team is lacking.  
 
6.3.1 Benzodiazepines 
30 years of research has shown that worldwide benzodiazepines are among the 
most frequently prescribed psychotropic drug. (246) According to the admissions’ 
count of the ‘Treatment Episode Data Set’ (TEDS) in the US, the figure 
representing the amount of clients requesting treatment for their BZD dependence 
virtually tripled between 1998 and 2008. (247) This data also indicates that BZDs 
are often concurrently misused in tandem with other drugs, most notably opioids. 
(247) Study 1 of this thesis confirmed this by revealing a particularly chaotic use 
of benzodiazepines (BZDs) amongst its individuals. Few studies show marginal 
clinical significance in the pharmacokinetic interactions between BZDs and 
opioids (248)  and therefore, it is likely that, it is their pharmacodynamic 
interactions, which underlie their co-abuse. To that end, preclinical research 
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indicates that the fulfilling and fortifying effects of opioids are increased by BZDs 
and this is likely the reason why they are used concurrently. (249) Synergistic use 
amplifies the μ agonist effects of opioids often resulting in opioid intoxication. 
(250) In 2011, Chen reported that among methadone individuals reporting a 
history of BZD use, greater than 45% responded that they did so to “get high,” 
“have a good time,” or “produce an intense, exciting experience.” (251) Research 
confounds the reports in Study 1 that injecting BZDs increases the euphoric effect 
of opioids. (252) Research also indicates that comorbid sedative use disorder is 
associated with increased rates of continuing opioid use. (253) 
Complications of BZD and opioid co-abuse are numerous, the most worrying 
being an increase is OD fatalities. (248) One’s respiratory drive is inhibited via 
the mu opioid receptor. BZDs augment the effect of GABA. GABA receptors are 
also highly concentrated in these respiratory centres and hence both opioids and 
BZDs, used separately or concurrently, are capable of altering respiration 
frequency. (248) Approximately half of all individuals with a heroin use disorder 
recount at least one non-fatal od (254), with BZDs being present in 50–80% of 
heroin-induced deaths. (255) Concurrent BZDs abuse with OATs also increase the 
risk of death, more so with complete agonists, for example, methadone. (256) 
Supporting these findings, internationally BZDs have been found in 40–80% of 
methadone-induced mortalities. (257) Irish figures also reflect this trend. As noted 
above, of the 209 individuals who died as a result of opioid drug over-dose, 179 
had two or more drugs implicated in their death, of which benzodiazepines were 
the most commonly found. (98) 
Most worryingly, the synergistic abuse of both opioids and BZD negatively 
affects naloxone’s ability to reverse respiratory depression in an OD. (248) 
Research indicates that in comparison to individuals with a sole OUD, concurrent 
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dependence on both BZDs and opioids results in individuals using opioid 
considerably longer, (258) in much higher quantities and are at an increased risk 
of abusing supplementary drugs (excluding BZDs). (259) Research also indicates 
that clients of MMTPs who had a co-morbid BZD disorder were prescribed larger 
methadone doses and more often abused alcohol. (258) Individuals in receipt of 
OAT worldwide appear to be particularly susceptible to a co-morbid BZD and 
Opioid use disorder as used concurrently it appears an individual can attain a 
more powerful opioid effect often described as “heroin-like.” Additional research 




This section expands on the myths surrounding methadone as a therapeutic agent, 
the clinical language used in relation to methadone and methadone programmes, 
the stigma associated with registration on a MMTP and finally clients’ own 
understanding of methadone as a therapeutic modality is explored.  
6.4.1 Myths encircling Methadone  
Methadone is a complex treatment modality and its complexity serves to fuel this 
myth. For over 50 years, we have known that individuals with OUDs require 
methadone to combat withdrawal symptoms and suppress cravings thereby 
freeing the patient from the daily cycle of searching for, purchasing, and 
consuming heroin. (137) As such, there is no denying they are hugely reliant on 
their medication and are very much likely to relapse to opioid abuse if treatment is 
suspended, much like a person diagnosed with schizophrenia would likely relapse 
if they missed their anti-psychotic medication. So in essence, yes, the individual 
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with an OUD is ‘dependent’ on their methadone but its place in their treatment 
plan allows them to attain abstinence from illicit opioid misuse and abuse. (260)  
The benefits on their mental and physical health and subsequently their overall 
better social integration are superbly well documented (261), but unfortunately 
not reaching society’s wider audience.  
From a therapeutic perspective, likely the largest myth surrounding the use of 
methadone is the belief that it is a ‘substitute’ for heroin and that ‘addicts’ are 
simply replacing one drug of ‘addiction’ with another. 
A second myth is based on the side effect profile of methadone as it is often cited 
to damage teeth and destroy bone health. Methadone does not directly affect teeth 
or bones. Intake of methadone may result in xerostomia, and the ensuing lack of 
saliva may increase one’s susceptibility to dental issues. Moreover, clients often 
commence methadone treatment after a long period of neglecting their dental 
hygiene. Individuals sometimes feel “bone ache” during treatment —likely 
reflecting the symptoms of their opioid withdrawal, which they incorrectly 
attribute to methadone. (262) However, as the following example a show, 
understanding of this, even in health advocacy circles, published in reputable 
journals is shockingly poor. Cleo Silvers, is a well-known, remarkable Bronx 
health activist and a much respected figure in health advocacy circles in the US 
with more than five decades of health advocacy experience—an activism notable 
for its insistence on the inextricable links between health and socioeconomic well-
being. In a 2016 interview she gave to Alondra Nelson, published in the American 
journal of Public Health, (263) she gave the following account of methadone.  
“We know the horrors of the use of methadone and all the horrible things 
that happen to people. Their bones become brittle; it eats the bone 
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marrow. It was the worst possible chemical to use to help people with drug 
rehabilitation.” Cleo Silvers, health activist.  
A letter refuting Silvers’ claims written by Lawrence Brown and Stephen Kritz 
(262) was submitted and subsequently published by the journal. Silvers declined 
to respond.  
6.4.2 Clinical language in relation to drug dependence 
The clinical language of ‘addiction’ only further shrouds methadone and 
methadone clinics in rumour, myth and misconception. Words like ‘abuse’ and 
‘abuser’ evoke perceptions of a willful, self -regulated action and that the 
individual is more of a ‘criminal’ engaging in deliberate misbehaviour. In 
reference to urine toxicology showing positive for opioids, the term ‘dirty’ carries 
obvious negative connotations. Labelling an individual by their illness with words 
like ‘addict’ or ‘junkie’ also increases stigma. To reduce prejudice and improve 
care we must use person-centred language, describing those with an ‘addiction’ as 
people with a substance, or in this case, opioid use disorder. Integral to this 
change is also the need to alter the language of treatment. The much cited medical 
term ‘substitution’ or ‘replacement’ therapy enforces the most widely held and 
stigmatizing belief that methadone is a ‘replacement addiction.’ The notion that 
opioid agonist treatment is not an effective stand-alone treatment is widely 
supported, even by some ‘addiction’ professionals (264) even though research 
repeatedly refutes this claim. (265) Since 2009, the WHO recommends to not 
withhold medication if someone refuses counselling (266) supporting the 
overriding efficacy of opioid agonist therapies such as methadone in treating 
OUD. It most certainly is not ‘substitution’ for an illicit drug. (267) 
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6.4.3 Stigma, specifically in relation to the therapeutic agent, 
methadone 
Notwithstanding its effectiveness and extensive use, treatment of OUD with the 
therapeutic agent methadone, remains shrouded in stigma. (268) Indeed, of all 
treatment modalities MMT evokes particularly potent shame. (269)  
From a clinical perspective, in study 1, individuals’ often-acrimonious 
relationship with their GP and the poor communication cited between allied-
health professionals in their lives often served to fuel their habit further. Abundant 
research supports the claim that individuals with SUDs encounter stigma from 
healthcare professionals. (270) Most worryingly, research on this phenomenon 
validates that stigma from healthcare professionals acts as a commanding negative 
influence on drop-out rates among people living with an array of stigmas. (271) 
This in turn may impede treatment retention in MMTPs. (269) This stigma often 
cited in the literate as ‘institutional’ stigma is well researched. (154)  
In study 1, the stigma participants experienced from not only the public, but also 
their own family and friends, served to heighten their embarrassment in relation to 
all aspects of their illness but most obviously methadone as a therapeutic 
modality. This is in keeping with other studies where very high percentages of 
individuals reported experiencing discrimination from family, friends and their 
neighbourhood. (269, 272, 273) Stigma from one’s familial and social network 
may hamper their interpersonal relationships and jeopardise their social support, 
both of which are fundamental for psychological wellbeing and attainment in 
treatment. (274)  
Finally, analysis of the transcripts in Study 1 revealed participants’ own self-
stigma (275) in relation to availing of methadone to treat their OUD, which is 
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another facet of stigma needing to be addressed. Self-stigma arises when 
individuals allow public attitudes and behaviours to become part of their own 
nature by unconscious assimilation. This more often than not leads to damaging 
ramifications for the individual, inclusive of lessening their self-worth and self-
regard. (276)  
6.4.4 Patients’ understanding of Methadone as a long-term, 
maintenance agent.  
Examining the transcripts from study 1 highlighted that a definite negative 
influence on individuals’ journeys was their own erroneous understanding of their 
illness and methadone’s place in its treatment. Research indicates that treatment-
seeking individuals are typically driven by acutely pressing conditions such as the 
symptoms of withdrawal and have limited insight. They understand that craving is 
the leading contributory factor for relapse but lack long-term disease awareness, 
which means they deny the chronic nature of their dependence. Affected 
individuals live in the ‘here and now’ and solely focus on their immediate 
circumstances. They equate spontaneous short-term abstinence with full remission 
and any subsequent relapse is viewed as an isolated episode. (277) Moreover, as 
was evident in the above study, it is just when individuals achieve relief from 
acute withdrawal that their insight often regresses, in the sense that on cessation of 
acute withdrawal they immediately believe they have full ‘control’ over their 
substance use. It is difficult for them to accept any relapse-prevention perspective, 
as they are often blind to the concept of OUD as a chronic relapsing disorder. The 
most unfortunate outcome associated with this misconception is the increased 
incidence of ‘drug-induced death’ rates as relapse, after a period of abstinence, is 
often a likely prequel to opioid overdose.    
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6.5 Drug-induced deaths  
‘Drug-induced deaths’, as seen in the next section of this thesis, are increasing 
annually. The number of ‘drug-induced deaths’ in Europe peaked at the start of 
the millennium as a result of the heroin epidemic which broke in the 1980s. 
(278)Most worryingly, a new record number for the countries reporting to the 
EMCDDA (28 EU Member States, Turkey and Norway) was registered in 2016, 
with a staggering figure of 9,138 OD deaths, the highest number ever recorded. 
(120) At an individual country level, the most recent data from a number of the 
countries with relatively robust reporting systems, including Ireland, shows an 
increase. (120)  
As most ‘drug-induced deaths’ result from the misuse and abuse of opioids, 
predominantly the injection of heroin, (89) the importance of THNPs cannot be 
over-emphasised. It is imperative that Ireland’s THNP functions optimally if ever 
we are going to effectively curtail this rising death toll. Through descriptive 
analysis, study 2 aimed to gain an overall appreciation of Ireland’s THNP. By 
analysing its reporting mechanisms, it aimed to uncover any areas of redress to 
optimise its register. Finally, as discussed in the literature review in this thesis, 
and as expanded upon below, the importance of transfer to hospital for on-going 
monitoring has never been more necessary as extremely intoxicating new 
synthetic opioids are emerging as a significant player in the increasing number of 
‘opioid-induced deaths’ in Europe. The new fentanyl derivatives, which account 
for the majority of the new opioids identified by the EMCDDA’s Early Warning 
system, are wreaking particular havoc. (279) Because of their high potency, 
minute quantities can be life threatening, due their ability to cause rapid and 
severe respiratory depression.  
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In an opioid OD, respiratory depression decreases the levels of circulating oxygen 
and if sustained can lead to loss of consciousness, multi-system failure and death. 
(280) Several risk factors influence the probability of OD, including, but not 
limited to, the category of opioid, its potency and the quantity of opioid that 
crosses the blood brain barrier. Personal factors inclusive of tolerance, current 
medical history, length of use and genetics add to its complexity. (89) 
Research confirms that the dearth of response or incompetent interventions by 
those present at the scene of an OD heightens the risk of the event having a fatal 
outcome. Reported contributing factors are limited experience in the skills of 
basic life support, inadequate access to naloxone or the dread or panic of legal 
ramifications for peers witnessing an OD. (281) These three specific factors all 
too often result in overdoses occurring in the domiciliary setting. A Norwegian 
study also confirmed that in the context of OD, emergency response times were 
more likely to be lengthier for private, home settings; additionally, these patients 
were less likely to attend hospital, post naloxone administration. (282) Therefore, 
it is imperative to train potential bystanders on how to recognise and appropriately 
respond to opioid OD, particularly peers in the home setting, through the rollout 
of THNPs.   
 
6.6 Ireland’s Take Home Naloxone Programme  
Currently, In Ireland, the person who takes the lead at an OD scenario must 
complete an electronic report on the course of events which transpired at the OD 
scene using excel software and subsequently email it to a nominee of the HSE. 
However, training in excel or indeed in the completion of this form is not part of 
the THNP training course. As such, not all trained users of naloxone particularly 
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hostel workers, outreach workers and the most important cohort to capture, peers, 
in the community, have the capacity to report their use of naloxone in the setting 
of an OD.  
6.6.1 Check Exercise Outcomes  
The initial check exercise on the reported use of naloxone nationally in 2017 
provided a strong argument for both revising this current reporting mechanism 
and simplifying the form’s existing content and structure.  
Firstly, the use of excel adds a layer of complexity to the reporting which, most 
likely, exacerbates its poor uptake.  
Secondly, there is no flow or sequential logic to the layout of the excel sheet.  The 
information collected is also unnecessarily excessive. In 2017, in an attempt to 
rectify this issue, the form was shortened but it remains tedious to fill and the use 
of confusing terminology confounds its ambiguity. An example being, the stand-
alone statement, ‘relationship to person providing information’. On data analysis, 
this response was often left blank or reported as ‘none’ as the information giver 
either did not understand the statement or was not directly related to the victim 
and as such, felt the appropriate answer was ‘none’. In addition, the person 
providing the information was not necessarily the person who administered the 
naloxone, which again confused the issue.  
Thirdly, it is imperative at an OD scenario that BLS is administered correctly. 
However, the current reporting mechanism does not lend itself to assessing this 
critical information. The line of questioning on the form does not establish from 
the outset if the victim was breathing or not. This is essential information. It 




Fourthly, a full section on whether the person was there or not at the exact time of 
the OD is also slightly redundant as information on ‘the length of time from point 
of using to OD’ and the ‘signs/symptoms of OD’ though interesting are very 
individual and likely beyond the scope of the current database’s remit.  
Listed in Chapter 7, section 7.5.1, are key recommendations on how to address the 
above concerns.   
6.6.2 Selected Dataset Analysis  
Subsequent to the check exercise, analysis of the selected dataset, showed the 
majority of naloxone uses were in Dublin (CHO areas 7 & 9) with the south-west 
region (CHO 3), containing Limerick City, the next largest. In this study, workers 
in homeless hostel shelters administered the vast majority of naloxone, 83%. The 
likely reason for this being the process involved in reporting an OD requires the 
time, presence of mind, interest in contributing to data collection nationally and a 
working understanding of excel. The only way a ‘peer’ can report the use of 
naloxone is by presenting to a recognised, institution or person equipped to 
complete and submit the on-line form on their behalf. As it stands, the majority of 
peers do not report use of naloxone. Literature indicates that fear surrounding 
involving law enforcement and subsequent repercussions, such as arrests, for the 
individual and the peers with whom they were using drugs at the time of OD still 
prevails. (283) In the US and Canada ‘Overdose Good Samaritan laws’ protect 
individuals who call for emergency support in the event of an OD from being 
detained or prosecuted for drug possession. These laws aim to embolden peers to 
call for the emergency services if they experience or witness a drug OD. As of 
July 2017, 40 states across the US had instituted Good Samaritan laws. (284) In 
Ireland, typically, as reflected in this study, the Gardai do not attend ODs, 
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however, no specific such laws are in place and though the general understanding 
is that the Gardai will not interfere with or make arrests at the time of an OD, 
there is no definite law in place stating same. The role of the Gardai is shrouded in 
obscurity,  and as such, it is very likely a deterrent to ‘peers’ to call for help, as 
this cohort of individuals already have a fractious relationship with authoritative 
bodies. This was reflected in the analysis of Study 2 where 100% of hostel 
workers appropriately called for 911 assistance in stark conflict to ‘peers’ who 
called for emergency assistance less than half of the time.  
As well as fear of arrest, (285-287), having misplaced confidence in their ability 
to manage the situation and resuscitate the individual themselves is cited in the 
literature for reasons as to why peers do not call for help. (286, 288) To address 
this issue, the importance of medical expertise at all OD scenarios must be 
reinforced at the time of training, and, thereafter, reiterated regularly at refresher 
update courses.  
Witnesses of overdoses, particularly peers, also worry they will be branded a drug 
user or ‘druggie’ if they bring attention to their affiliation with the OD victim, 
suggesting stigma can also make people less willing to call for help. (289) 
Chronic unemployment and subsequent reliance on social welfare benefits 
coupled with homelessness have played a role in the negative perception society 
as a whole has of individuals with an OUD. Augmenting this negativity, during 
the course of their dependency, individuals often develop stigmatizing illnesses 
such as AIDS and hepatitis C. Finally, co-morbidities with mental illness, 
particularly within the judicial system, intensify this damaging opinion and serve 
to stigmatise individuals with OUDs even more within society. (290)  
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From a gender perspective, the most recent Irish statistics show that under one 
third of the estimated opioid users in Ireland are female (88) and as such one 
would not predict that they would account for greater than half of the dispensed 
naloxone uses in Ireland. However, analysis of data recorded on Ireland’s national 
THN database showed females received naloxone slightly more often than males, 
56% versus 44%. A finding which surprisingly is in keeping with some literature 
elsewhere (291) but the majority of research to date indicates that females 
typically receive naloxone less frequently than males in the OD setting. (292, 293) 
From the perspective of age, over half of the dataset were aged between 30 and 
40, with the average age being just over 33. This is in keeping with current 
findings, reflecting that 60% of Ireland’s opioid users fall in the 35—64 age 
category, in comparison to less than one-third in 2006, signifying a certain ageing 
cohort effect. (88)  
In this study, the majority of OD victims were registered on a MMTP. This may 
be reflective of the fact that the majority of recorded uses of naloxone were in 
homeless shelters. Often those affiliated with community services such as housing 
also engage with community services such as drug treatment as they are au fait 
with being in the system engaging with service providers across a spectrum of 
their needs. Ireland is also recognised as being among the countries with a higher 
percentage of opioid users receiving OAT in Europe as identified by the 
EMCDDA in their 2018 Drug report.(82) 
It was only known in 3 instances of the recorded instances of OD that drugs had 
not been injected, with definite signs or reports of injecting in greater than 60% of 
cases. This is in keeping with international findings where individuals lacking 
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obvious signs of intravenous drug abuse such as drug equipment or ‘track marks’, 
were three times less likely to receive naloxone. (292) 
Only 11% of cases in this study were alone at the time of initial OD, with 1 or 2 
people being the most common occurring grouping in attendance. This is in 
keeping with other Irish (294) and international findings (295) and supports the 
use of naloxone by laypersons in the community setting.  
Distribution of doses administered was almost uniform, with 1, 2 and ‘3 or more’ 
doses having almost the same number of instances of use. Naloxone 
administration is like balancing on a tightrope, offsetting reversing opioid toxicity 
with avoiding opioid-withdrawal syndrome, as frequent incidence of the latter 
may lessen the readiness of peers to administer naloxone in the setting of an OD. 
(296) As the following excerpt from Lewis Brown, who has experienced recurrent 
opioid overdoses, indicates withdrawal symptoms are often why patients refuse 
hospital attendance. (297) 
“Diarrhea, throwing up, nose snotting, cold shakes, you know, you don’t 
want to feel that. So, instead of going to the hospital and getting more 
treatment, I went and got more heroin. The same thing that just almost 
took my life, I ran right back and got again.”  
However, the risk of under-medicating with naloxone, far outweighs the possible 
menaces of advancing opioid withdrawal, as the latter is disagreeable but rarely 
fatal, while not adequately reversing the respiratory depression associated with 
opioid overdose is frequently fatal, especially as the rates of OD due to powerful 
synthetic opioids increases. (280)  
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6.6.3 Hospital Attendance Post Naloxone Administration   
For the instances where the ambulance attended, less than half of the recipients of 
naloxone attended hospital. This is in keeping with current literature. (298) The 
absolute necessity for hospital attendance in today’s opioid problem is outlined in 
the following section. Most worryingly, in today’s opioid crisis, proliferating and 
unrelenting contamination of heroin with synthetic opioids that have volatile or 
unidentified pharmaco- and toxico-kinetics is on the rise. These novel fentanyl 
‘spinoffs’ are highly intoxicating substances that pose a somber danger to both 
individual and public wellbeing. Evidence of the devastating consequences of 
their use is evident in the US where deaths due to illicit opioid overdose have 
reached historic proportions (299). Opioid overdose is that widespread that the 
American Heart Association include naloxone in its ‘emergency response 
algorithms.’ (300) Worldwide, OD rates due to heroin- and fentanyl are 
increasing. Overdose rates have increased by 327% in Canada, 64% in the United 
Kingdom and 61% in Australia. (301) In Ireland, prior to 2011 no deaths were 
recorded because of fentanyl abuse. However, by 2015, fentanyl was implicated in 
7 deaths. (302) 
In this era of protean heroin adulterants, the most experienced of toxicologists are 
obliged to admit that the only thing we do know about the current heroin epidemic 
is that heroin is no longer just heroin. (303) Hospital monitoring is not just 
necessary for those who have injected opioids as orally consuming counterfeit 
pills containing fentanyl may lead to a delayed OD necessitating repetitive 




With the increased incidence of heroin adulterated with synthetic opioids such as 
fentanyl, counterfeit products, and the advent of novel opioids with unknown 
pharmaco- and toxicokinetics, we can no longer safely predict a patient’s 
naloxone requirement or the safest duration of observation. Until more data exist 
regarding pharmacokinetics, toxicokinetics, and expected clinical effects 
following exposure to synthetic opioids, it is prudent to ensure both hospital 
transport after naloxone administration in the community and a period of 
observation in the Emergency Department of at least 4 hours. (303) 
After reversal of respiratory depression, it can occur that a patient’s breathing 
centre is re-suppressed, a phenomenon known as ‘recurrence of toxicity’. 
Naloxone’s ability to block opioid receptors may wear off, as its half-life may be 
less than some of the newer synthetic opioids. This in turn may lead to relief from 
withdrawal symptoms but with re-emergence of respiratory depression. To quote 
Clarke et al. (305), ‘clinicians are clearly walking a tightrope between 
precipitating acute withdrawal symptoms and avoiding recurrence of toxicity’. 
Moreover, the duration of time for which further monitoring is required is 
dependent upon the class of opioid used which is often not known by the 
paramedics assessing the case and with today’s market rife with new emerging 
synthetic compounds it is even more difficult to judge. (306) 
This potential for ‘recurrence of toxicity’ following a preliminary reversal with 
naloxone is well recognised in peer-reviewed literature for over 20 years. (307, 
308) This phenomenon can be fatal, particularly if an OD victim declines hospital 
transfer or self-discharges against medical advice on arrival at the hospital. (279) 
Another valid reason for hospital attendance is that reports of recent non-fatal OD 
are independently associated with subsequent OD mortality. (309) Individuals 
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who suffer non-fatal OD should engage with intensive OD prevention 
interventions in order to reduce subsequent OD mortality among opioid users. The 
most appropriate place to initiate this intervention is in a secondary setting such as 
a hospital as soon after the OD event as possible.  
For the above reasons, attendance at hospital is essential. However, as is evident 
from study 2, in which 40% of victims refused to attend hospital, and many others 
internationally (298) attendance at hospital is sub optimal.  
The LR Model generated in this study allows us to predict the likelihood of 
patients attending hospital. However, it must be recognised that the Irish THN 
Programme is not yet 3 years established and as a result, our sample of 100 uses 
of naloxone, is small. With such a limited sample size, we had to include variables 
with borderline significance. Ideally, the LR Model should be tested on a larger 
cohort of clients to ensure validity.  
Results showed that a patient receiving 3 or more doses of naloxone was a highly 
significant factor in determining hospital attendance, (P value of 0.01). 
Subsequent analysis using Welch’s t-test assessed what factors, if any, influenced 
the number of doses received. The age of the person who overdosed (p-value 
0.06) was shown to be the only significant factor, which is in keeping with 
international findings. (310)  
Thereafter, the two most significant factors influencing hospital attendance was 
gender and registration on a MMTP. Male patients had a negative borderline 






Chapter 7 Summary and Recommendations 
7.1 Chapter Summary 
This chapter concludes the thesis and provides key recommendations. Its structure 
mirrors the chosen themes of the discussion chapter. Initially recommendations 
will focus on how knowledge of ACEs should influence the MMTPs in Ireland 
and internationally, to adopt a more ‘trauma informed’ ethos. Subsequently, 
recommendations will centre on dually diagnosed individuals, with a specific 
focus on addressing benzodiazepine misuse. Next, the theme of therapeutics will 
be explored, listing specific proposals on how to both promote education and 
reduce stigma in relation to methadone, as a treatment option in OUD. Finally, the 
thesis will focus on recommendations with regard to THNPs. Initial suggestions 
will focus on improving the Irish THNP and subsequently general 
recommendations applicable to THNPs internationally will be addressed.    
 
7.2 The role of ACEs in influencing a ‘Trauma Informed’ 
MMTP 
In giving appropriate recognition to the influential role ACEs have on both 
developing and sustaining an OUD, MMTPs in Ireland and internationally should 
ensure their programmes are ‘trauma informed’. Specific stages necessary to 
create a high quality, functioning ‘trauma informed service’ should include an 
evaluation of the incidence and magnitude of the ‘trauma loaded environment’ 




In both acknowledging and understanding the prevalence and impact of ACEs in 
their clients’ lives all employees of a Drug and Alcohol service will have a better 
appreciation of the multifaceted and diverse journeys clients travel in search of 
healing and recovery.  Trauma informed training delivered to all staff would also 
be essential in ensuring they respond appropriately to clients’ revelations.  
As is evident in the above thesis, ACEs play a central role in the potential 
development of an opioid use disorder. From a European perspective, the 2015 
Welsh study on ACEs (25) contributed most significantly to our understanding of 
the importance of identifying ACEs and intervening to halt their progression as 
soon as possible. Wales is currently pioneering a broad scope of procedures and 
processes from which Ireland and others internationally could learn.  
One such programme is, ‘The Building a Brighter Future: Early Years and 
Childcare Plan 2013-2023’ (311) which aim to address the following:   
1. Ensure that knock-on adversities from substance misuse  and abuse are 
uncovered, tackled and their influence on children reduced 
2. Detect and intervene where children may already be experiencing 
adversities  
3. Equip families with the appropriate competencies to prevent ACEs 
occurring within the home setting  
MMTP are the ideal setting for these improvements to be addressed.  
7.2.1 ACEs and Resilience  
In physics, resilience is the capability of a substance to absorb energy (such as 
from a knock) and discharge that energy as it ‘springs back’ to its initial profile. 
This physical phenomenon is comparable to a person’s aptitude to ‘spring back’ 
after an unsettling life event. Within the context of ACEs, resilience can be 
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viewed as a person’s capability to sidestep damaging behavioural and 
physiological alterations because of chronic stress. Some individuals are born 
with an innate resilience, most others have received external supports and 
guidance to attain the resilience necessary to adjust effectively to stress, trauma 
and long-term adversity. (312) To complement the ACE questionnaire, ‘resilience 
questionnaires’ are employed (313-315) to establish if children have the necessary 
support structures available to them to help minimise the short and long-term 
effects of ACEs on their current and future well-being. Once more, MMTPs are 
ideally placed to identify these at-risk children and work with public health bodies 
to ensure those at risk have the necessary armour to protect against ACEs and the 
skill set required to develop and sustain resilience.  
7.2.2 Stress Management 
Study 1 of this thesis highlighted the critical role clients’ stress played in both 
developing and sustaining an OUD. In the treatment of OUD, incorporating a 
focus on stress and its management improves treatment outcomes. (235) 
Evidently, there is a considerable public health cost associated with drug use and 
such improvements in the treatment of clients’ stress would pay a sizable dividend 
to all. Tailored interventions for the treatment of stress in individuals’ with an 
OUD from psychologists, counsellors, nurses, psychiatrists and General 
Practitioners (GPs), all working collaboratively, would have far-reaching benefits. 
7.3 Dual Diagnosis 
Goals for effective change for dually diagnosed clients should focus on 
collaboration between and education of all stakeholders (both statutory and non-
statutory).  It is vital that mental health staff receive drug and alcohol awareness 
training. Similarly, staff of the drug and alcohol services should receive mental 
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health training. This would enable staff to better refer and work collaboratively. 
Information sessions delivered by counsellors and psychologists to relevant 
stakeholders would be beneficial. Multi-disciplinary forums would allow staff to 
tease out challenges and capitalise on opportunities with clients. The advantages 
of well-trained staff are obvious as inevitably this will improve results and make 
for a more efficient MMTP. 
To address the need for better services in relation to Dual Diagnosis, the HSE 
Mental Health division in conjunction with the College of Psychiatrists has set up 
a Clinical Programme (CP), entitled, ‘Co-morbid Mental Illness and Substance 
Misuse’. The overall aim of this CP is to design and progress an evidence-based 
model of care for the treatment of co-occurring mental and substance use 
disorders nationally. Integral to the overall plan will be the development of 
‘Community Dual Diagnosis Teams’ with access to inpatient drug treatment and 
rehabilitation units. Recent research would suggest on-site and combined mental 
health and substance use disorder services in a MMTP might improve mental 
health outcomes compared with off-site, non-combined care. (316) The HSE has 
set a tight timeframe of 2 years from the establishment of this CP to mainstream 
operation in Mental Health Services. As such, this group is expected to finalise 
the Model of Care in 2019 with a subsequent roll out of the programme 
nationally. Our study highlights the need for this strategy and identifies the need 
to ensure funding remains in place for its completion and maintenance thereafter.  
7.3.1 Benzodiazepines 
A significant proportion of deaths result from poly-substance use, chiefly the 
mixing of heroin with other depressors of the central nervous system, such as 
BZDs. (317) To address this issue locally, the HSE Addiction service, the ICGP 
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and Novas, an NGO service, support the ‘Mid-West community detox 
programme’. The primary aim of this programme is to help individuals wishing to 
access secure, structured detoxification from BZDs, in an outpatient setting. 
Clients’ family practitioners, key workers and community-based partner 
organisations all work together to offer a personal, tailored care plan to each 
client.  
Established in 2012, the programme operates from the HSE Mid-West Limerick 
MMTP’s offices, Slainte, 2 days a week. The programme is an excellent example 
of how two services, run out of the same establishment could work 
synergistically, for the benefit of the individual with a dual dependency.  Clients 
of the MMTP with a concurrent BZD dependence can avail of their timely on-site 
support at the time of their assigned weekly methadone clinic. Potentially, it 
allows the methadone team to work in conjunction with the BZD team to optimise 
a tailored care plan for each respective client. However, the actual workings of 
this programme need addressing.  
Firstly, a current key requirement of the ‘Mid-West community detox programme’ 
is that opioid dependent clients must be ‘opioid -free’ for a minimum period of 1 
month prior to being able to approach a GP in the community to request BZD 
detoxification. Unfortunately, given their opioid dependence, this period of 
abstinence is not always feasible and often restricts those in most need of 
detoxification, in being able to avail of the service. Often clients, in their 
understandable quest to detoxify from BZDs, give false negative samples for 
testing, in attempt to attain the required number of opioid free urinalyses.  
Thereafter, even if a client does meet the requirement of remaining free from 
opioids for the specified duration, GPs in the community are not always readily 
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available and willing to engage with clients to address their needs. The quantities 
of prescribed BZDs necessary to initially stabilise and then commence 
detoxification are typically well in excess of recommended daily guidelines for 
the general population, and day-to-day GPs in the community feel inexperienced 
to prescribe same.  
A recommendation to address the above would be to have experts, both nationally 
and internationally, in this area create a specific policy on prescribing larger than 
typical doses of BZDs to concurrently dependent opioid users which would give 
GPs the knowledge, confidence and legal backing to adequately address this 
cohorts’ needs.  
Of note, Novas functions primarily as a housing organisation helping the 
homeless or those who are at risk of being homeless. Operating on a voluntary 
basis, it recognises the multifaceted reasons, which result in homelessness, most 
notably, SUDs, and endeavours to contribute to all-inclusive, longstanding 
resolutions, such as the programme above. A subsequent recommendation is to 
ensure to continue to have their expertise and resources in addressing 
homelessness available to the clinic and for this clinic and all clinics to expand 
and engage with other homeless organisations, as many of the clients grapple with 
remaining in secure accommodation. This approach is supported in our National 
Drug and Alcohol strategy via action 2.1.12: ‘Strengthen the implementation of 
our National rehabilitation framework via key working, care planning and case 





Recommendations on this issue were borne from the clients of the HSE Mid-West 
Limerick MMTP, when in Study 1 of this thesis they impressed upon the need to 
educate not only themselves but also their doctors, friends, family and the public 
as a whole on the therapeutic rationale and associated benefits underpinning 
methadone as a treatment option for OUD. This is insightful and warrants further 
exploration. Thereafter, the pivotal role stigma in relation to methadone treatment 
plays in perpetuating OUD is explored.  
7.4.1 Education   
Advances in our understanding of the neurobiological processes that arise 
following acute and chronic opioid consumption have helped enhance our 
scientific understanding of how dependence develops. However, the concept of 
‘neurobiology of dependence’ is exceptionally complex and as a result often 
poorly understood, even amongst professionals in the medical community. 
However, developing an understanding of the neurobiology of drug dependence 
can be extremely valuable to the clinician. It can offer an insight into individuals’ 
behaviours and difficulties, which in turn can help establish patient centred 
attainable objectives and define the over goal of their treatment plan. (318) 
Clinicians need to first educate themselves and subsequently impart evidence-
based truths with regard to the habit-forming processes which underlie opioid use 
disorder, to not only their clients but also their clients’ families and the general 
public to optimise the functioning and overall success of any MMTP.  
From a client perspective, health care professionals collectively must work with 
OAT clients at their level, to educate them on the neurobiological origins of their 
opioid dependence. Clients in turn will benefit from understanding that the 
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biological basis of their illness is in need of long-term, often life-long therapy. On 
a positive note, individuals in study 1 and for over 40 years internationally (319), 
acknowledge methadone’s ability to curb dependence and this unwavering belief 
should be integral to build on their psychoeducation.   
The term ‘psychoeducation’ in opioid dependence refers to a form of 
communication between the clinician and their client that acknowledges the 
client’s role in understanding and dealing with the realities of their illness.  
One such stark reality is the need for clients to act appropriately to ensure their 
methadone is stored appropriately. A study conducted in Ireland in 2016 revealed 
that though study 97% of patients were aware of the dangers of methadone use 
86% did not place their take-home methadone in a locked place. (320) 
The overall purpose being to get the client to believe in the efficacy of their 
treatment to improve their adherence, which in turn should reduce the occurrence 
of relapse and most importantly, ‘drug-induced death’ rates.  
Familial members must also be educated on the over-riding benefits of methadone 
as a therapeutic agent. Acceptance and support from a client’s family is pivotal in 
their ability to adhere to their treatment plan. Insightful appreciation of the 
complexities of OUD by the client’s familial network is key influences on their 
rehabilitative journey. (321) Research proves that individuals with an OUD 
profiting from family assistance fared better from a treatment outcome 
perspective. (322) 
Broadening on the theme of education, the public needs to be educated not only 
on the benefits of methadone but also on the over-riding benefits of harm 
reduction policies in the fight against OUD. Ireland can learn from internationally 
initiatives. For example, the provision of drug paraphernalia to aid the injecting of 
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drugs, which understandably could be viewed by many as ‘ludicrous’ (323) was 
successfully reframed by Switzerland as a policy to reduce the spread of HIV. 
(324) In doing so, Swiss society could immediately see the tangible benefit of the 
initiative and supported it wholly. In addition, OUD spans all classes of society. 
Vancouver, Canada used this evidence to gain national support to fund harm 
reduction initiatives (325) and in doing so brought all classes of society together 
to collectively tackle its opioid crisis. Vancouver and Switzerland are examples of 
how ‘positive spin’ can sway societal attitude and entice people to work 
collectively, which has the possibility to affect positive change. 
If we do not take this, three prong approach to educate clients, their families and 
the public on the overriding benefits of methadone as a treatment modality in the 
fight against OUD the negative effects of stigma will not only prevail but also 
ultimately triumph.  
7.4.2 Stigma 
Paradoxically, stigma serves to amplify drug use in individuals with a SUD as 
they use it as a coping strategy to combat the stress and negative sentiments 
inextricably linked with discrimination. (326) For clients of a MMTP, using drugs 
in this way may have remarkably negative significances on clients’ mental health 
and recovery endeavours. Given its prevalence, it is critical for society as a whole 
to address this stigma. In Ireland, policies and ideological points of view are 
shifting into more preventative, holistic, patient centred models. However, stigma, 
blame, and competing ideologies continue to exist in relation to the optimal means 
to treat drug dependence. (81, 327, 328) 
Ireland must learn from successful international initiatives. Vancouver, Canada 
successfully brought a broad range of stakeholders together, with expertise 
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straddling many fields (political, academic, legal and community based) to 
concentrate on finding a united resolution to the opioid crisis. (329)  
The current approach of our National Drugs and Alcohol Strategy, ‘Reducing the 
Harm and Supporting Recovery’ does bring together many of the key players 
from the Community and Statutory arenas to address the issue more 
comprehensively. 
 
7.5 Take-Home Naloxone Programmes 
This section will first review specific recommendations with regard to Ireland’s 
current reporting mechanism on the uses of naloxone nationally. It will then 
broaden its scope to incorporate general recommendations with regard to 
improving the effectiveness of THNPs.  
7.5.1 Specific recommendations regarding the reporting of 
naloxone uses in Ireland 
The check exercise on the recorded uses of naloxone in Ireland in 2017 afforded a 
clear rationale for both amending the current reporting mechanism and 
streamlining the form’s current layout and line of questioning.  
7.5.1.1 Mechanism to report naloxone use in the Irish Community 
setting  
A better, more user-friendly system would be to revert to the manual report, 
which could be in the packaging of each naloxone kit. The HSE should restrict the 
information recorded to the absolute minimum, perhaps just the simple 15 
questions drawn from the data set for this study. Importantly, this would also be in 
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line with the EU General Data Protection Regulation, which took effect on May 
25th 2018 as the current format requests potential identifiers not in line with these 
regulations. On receipt of the paperwork a nominated individual within each CHO 
area could submit an excel sheet once monthly to the HSE on its recorded uses of 
naloxone. 
7.5.1.2 Clarifying the details required on the form  
It is beyond the scope of this thesis to address all the potential amendments that 
could be made to the current THNP reporting form in use in Ireland. Here, we will 
just address two issues raised in the discussion section of this thesis.  
Firstly, in respect to the line of questioning on the ‘relationship between the 
person filling the form and the patient’ a clearer line of questioning would be: 
1. Did you administer the naloxone? If not, who did?  
2. Are you a relative or personal friend or working at the site of the 
overdose? - Please circle as appropriate. If none of these describes your 
relationship with the victim can, you explain how you happened to be 
present at the scene of the overdose.  
Secondly, and most importantly, from a BLS perspective, the effectiveness of 
BLS training in the context of THNPs is not assessable from the current reporting 
mechanism. Current training teaches that if a patient is not breathing, the 
appropriate next step is to contact the emergency services and then administer 
CPR, 30 cycles of chest compressions followed by 2 rescue breaths. After one 
round of CPR, naloxone should then be administered. However, if a patient is 
unarousable but breathing normally, the correct next step is to place them in the 
recovery position and administer naloxone. Therefore, a better way of assessing 
witnesses’ appropriate use of BLS would be to segregate the two pathways of 
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BLS administration after clarifying if their patient was or was not breathing on 
their arrival at the OD setting.  
7.5.2 General Recommendations regarding THNPs 
A clear deterrent to both the calling for assistance and reporting of naloxone use 
by peers is the fear of legal prosecution. Ireland and other countries 
internationally could benefit from adopting a similar approach to the US and 
Canada in combatting this fear by introducing ‘Overdose Good Samaritan laws’ 
which safeguard peers from being incarcerated or impeached for drug possession 
in the setting of an OD.  
Stigma also plays a critical role in hampering appropriate peer management of an 
OD as it negatively influences peers to call for help or report the events 
retrospectively. A resolution to the detrimental repercussions of stigma will not be 
found until the misinterpretations about all aspects of OUD and its treatment are 
addressed, challenged, and explained. This may be achieved with affected 
individuals and relevant authorities collaborating in an extensive, coordinated 
media-based national effort. (330) 
The LR Model generated in Study 2 permits first responders and paramedics to 
pre-empt the likelihood of a patient refusing hospital attendance. This allows both 
parties to be pre-warned as to the potential volatility of the patient in question and 
allow them to prepare accordingly, perhaps in the case of paramedics for a more 
experienced team to be deployed to certain overdose situations. Secondly, it 
highlights those who may specifically benefit from education on the necessity of 
hospital attendance. Accounting for the small dataset in Study 2, a specific 
recommendation of this thesis is to test the validity of the LR model on a bigger 
international dataset. Thereafter, its findings should be employed to inform first 
157 
 
responders and emergency personnel on the likelihood of their patient attending 
hospital. Secondly, the overwhelming benefits of hospital attendance should be 
impressed upon the specific cohort who the model predicts to be likely not to 
attend hospital in a targeted educational campaign.  
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7.6 Chapter Conclusion  
One of the largest obstacles restraining our combined capacity to tackle the opioid 
problem not only in Ireland but worldwide, is the un-coordinated, mismatched 
concepts of suitable resolutions.  
Relevant stakeholders in the medical, pharmacological, public health and legal 
fields as well as all community-based programmes differ significantly in their 
beliefs regarding the best, most appropriate solutions to tackle the opioid crisis. 
(107) It is critical to align philosophical beliefs and public attitude with evidence 
based research, if we are ever to develop and implement effective policies and 
programmes to address this epidemic.  
Recommendations from the evidence-based research conducted in study 1 of this 
thesis aimed to do just this. MMTPs are integral to addressing the opioid 
dilemma. Ensuring these programmes function optimally is a critical step in 
tackling the problem. Incorporating the voice of the clients themselves on how 
best to optimise these programmes’ objectives shone new light on the issues. In 
summary, having a ‘trauma informed’ MMTP, which places appropriate 
importance on both clients’ ACEs and client resilience, is essential. A key step, 
identified in this study, in achieving this is addressing clients’ stress management. 
Another outcome of this study was the importance of appropriately servicing dual 
diagnoses in clients with OUD, particularly their dependence on BZDs, which is 
starkly evident throughout this research. The importance of imparting applicable 
knowledge to all relevant stakeholders in OUD was a recurrent important theme. 
Professionals need to be educated on the neurobiology of dependence and clients 
need intensive psychoeducation. Familial members need to be informed of the 
pharmacological benefits of methadone as a treatment not a substitute for opioid 
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dependence. Finally, the public need to be instructed on the harm reductive 
benefits associated with appropriate OUD treatment, which dramatically improve 
the societal burden of the disease. This in turn should lessen the overriding stigma 
associated with OUD.  
Secondly, optimising THNPs worldwide will improve the death rates associated 
with OUD. Understandably, each THNP works within its country’s legal and 
economic framework but all programmes can learn from the research conducted in 
study 2 of this thesis. Ensuring an appropriate, accurate, succinct reporting 
mechanism is in place on the use of community naloxone would be beneficial to 
all. Safeguarding that peers who report naloxone use are protected by well 
established, publically advertised good Samaritan laws would increase the 
reporting of naloxone use in the most vulnerable and chaotic of cohorts, those 
with OUDs themselves. Gaining a better understanding of this cohort would be 
most beneficial to appropriately addressing their needs.  
Finally, the logistic regression model generated in study 2 of this thesis, which 
predicts the likelihood of patients attending hospital post naloxone, has the 
prospect to better equip first responders on the potential volatility of their patient 
and secondly allow relevant services to identify and target those least likely to 
avail of secondary care.  
Researchers play an integral, pivotal role in forming future policy regarding OUD 
through the dissemination of evidence-based knowledge. In doing so they 
contribute significantly to the quality of public discourse and debate which 
ultimately should unify society’s approach to tackle OUD. It is hoped that the 
findings of this thesis, in line with other research (107), will inform policy 
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makers’ decisions regarding how best to tackle OUD and will motivate them to 
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